<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4394</journal-id><journal-id journal-id-type="pmc-domain">dadr</journal-id><journal-title-group><journal-title>Drug and Alcohol Dependence Reports</journal-title></journal-title-group><issn pub-type="epub">2772-7246</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10040330</article-id><article-id pub-id-type="pmcid-ver">PMC10040330.1</article-id><article-id pub-id-type="pmcaid">10040330</article-id><article-id pub-id-type="pmcaiid">10040330</article-id><article-id pub-id-type="pmid">36994370</article-id><article-id pub-id-type="doi">10.1016/j.dadr.2023.100133</article-id><article-id pub-id-type="pii">S2772-7246(23)00003-3</article-id><article-id pub-id-type="publisher-id">100133</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Heidbreder</surname><given-names initials="C">Christian</given-names></name><email>Christian.Heidbreder@indivior.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Fudala</surname><given-names initials="PJ">Paul J.</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Greenwald</surname><given-names initials="MK">Mark K.</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><aff id="aff0001"><label>a</label>Indivior Plc, North Chesterfield, VA, United States of America</aff><aff id="aff0002"><label>b</label>Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, United States of America</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>Christian.Heidbreder@indivior.com</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2023</year></pub-date><volume>6</volume><issue-id pub-id-type="pmc-issue-id">430715</issue-id><elocation-id>100133</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>6</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>9</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-14 14:25:36.750"><day>14</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors. Published by Elsevier B.V.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0001">The discovery of buprenorphine in 1966 revolutionized care for opioid use disorder.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0002">US government and private industry partnership led to buprenorphine-based medications.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0003">Confronting barriers to use these medications is critical to address the opioid crisis.</p></list-item></list></p></abstract><abstract id="abs0002"><p>Buprenorphine-based medications were first approved by the United States Food and Drug Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) as the condition is presently known. This regulatory milestone was the outcome of 36 years of research and development, which also led to the development and approval of several other new buprenorphine-based medications. In this short review, we first describe the discovery and early development stages of buprenorphine. Second, we review key steps that led to the development of buprenorphine as a drug product. Third, we explain the regulatory approval of several buprenorphine-based medications for the treatment of OUD. We also discuss these developments in the context of the evolution of regulations and policies that have progressively improved OUD treatment availability and efficacy, although challenges remain in removing system-level, provider-level, and local-level barriers to quality treatment, to integrating OUD treatment into routine care and other settings, to reducing disparities in access to treatment, and to optimizing person-centered outcomes.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Buprenorphine</kwd><kwd>Formulations</kwd><kwd>Opioid use disorder</kwd><kwd>Medication development</kwd><kwd>Regulatory approvals</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0004">In 2020, an estimated 9.5 million Americans aged 12 or older misused opioids, 2.7 million met criteria for opioid use disorder (OUD) (<xref rid="bib0002" ref-type="bibr">American&#160;Psychiatric Association,&#160;2013</xref>), and 278,000 received treatment in the past year for OUD (<xref rid="bib0110" ref-type="bibr">SAMHSA,&#160;2021a</xref>). The opioid crisis has also been compounded by the coronavirus disease 2019 (COVID-19) pandemic as well as co-use or contamination of psychostimulants with illicitly manufactured fentanyl or heroin (<xref rid="bib0058" ref-type="bibr">Jones&#160;et&#160;al., 2020</xref>; <xref rid="bib0093" ref-type="bibr">Niles&#160;et&#160;al., 2021</xref>). Individuals with OUD are at higher risk for COVID-19 (<xref rid="bib0126" ref-type="bibr">Wang&#160;et&#160;al., 2021</xref>) among patients with a substance use disorder and are particularly vulnerable to treatment interruption, isolation, and stress, all of which can trigger misuse of prescribed opioids, illicit opioid use, and return to opioid use (<xref rid="bib0098" ref-type="bibr">Rodda&#160;et&#160;al., 2020</xref>). Early in the pandemic, drug testing revealed increased positivity rates for non-prescribed fentanyl (+35%), heroin (+44%), and opioids (+10%) (<xref rid="bib0058" ref-type="bibr">Jones&#160;et&#160;al., 2020</xref>). Since then, multiple studies in the United States (US) have shown increases in opioid-related mortality and emergency department visits (<xref rid="bib0126" ref-type="bibr">Wang&#160;et&#160;al., 2021</xref>; <xref rid="bib0052" ref-type="bibr">Holland et&#160;al., 2021</xref>; <xref rid="bib0105" ref-type="bibr">Slavova&#160;et&#160;al., 2020</xref>). The predicted provisional number of opioid overdose deaths in the US increased to 81,857 in the 12-month period ending in February 2022, up from 72,930 the year before in February 2021 (C<xref rid="bib0016" ref-type="bibr">DC,&#160;2022</xref>). Synthetic opioids alone accounted for 72,758 overdose deaths in the US during the same period (C<xref rid="bib0016" ref-type="bibr">DC,&#160;2022</xref>). More than ever, it is critical that individuals suffering from OUD receive efficacious, evidence-based treatments.</p><p id="para0005">A significant breakthrough in the treatment of opioid dependence, or OUD as the disorder is presently known (<xref rid="bib0002" ref-type="bibr">American&#160;Psychiatric Association,&#160;2013</xref>), occurred in the US during the 1960s with the expansion of methadone treatment and a publication by Dole and Nyswander describing the treatment of chronic heroin users with orally-administered methadone (<xref rid="bib0022" ref-type="bibr">Dole&#160;and Nyswander,&#160;1965</xref>; <xref rid="bib0055" ref-type="bibr">Jaffe&#160;and O'Keeffe,&#160;2003</xref>). However, the Federal Register methadone regulations of 1972 (<xref rid="bib0119" ref-type="bibr">US&#160;FDA,&#160;1972</xref>) and the Narcotic Addict Treatment Act (NATA, <xref rid="bib0089" ref-type="bibr">1974</xref>) of 1974 limited methadone maintenance treatment to opioid-treatment-programs (OTPs) &#8211; &#8220;methadone-clinic&#8221; settings (<xref rid="bib0054" ref-type="bibr">Institute&#160;of Medicine,&#160;1995</xref>) &#8211; and thus established a closed and highly-regulated distribution system for methadone such that patients could only receive methadone treatment in the context of an OTP. This restricted OTP system was geographically biased toward urban centers, with greater representation of economically disadvantaged individuals, Blacks, and other minorities, which regrettably contributed to racial disparities and stigma in treatment for OUD (<xref rid="bib0005" ref-type="bibr">Andraka-Christou,&#160;2021</xref>; <xref rid="bib0044" ref-type="bibr">Gryczynski&#160;et&#160;al., 2011</xref>; <xref rid="bib0050" ref-type="bibr">Hansen&#160;et&#160;al., 2016</xref>; <xref rid="bib0097" ref-type="bibr">Pro-and Zaller 2020</xref>; <xref rid="bib0109" ref-type="bibr">Stein&#160;et&#160;al., 2018</xref>). A transformational and radical move to bring OUD treatment to the mainstream of medical care took place in October 2000 with the passage of the Children's Health Act (P.L. 106&#8211;310), with Title XXXV of the Act providing a &#8220;Waiver Authority for Physicians Who Dispense or Prescribe Certain Narcotic Drugs for Maintenance Treatment or Detoxification Treatment of Opioid-Dependent Patients.&#8221; This part of the law is commonly known as the Drug Addiction Treatment Act of 2000 (<xref rid="bib0023" ref-type="bibr">DATA&#160;2000</xref>) (<xref rid="bib0023" ref-type="bibr">DATA&#160;2000</xref>, 2000). Under the provisions of <xref rid="bib0023" ref-type="bibr">DATA&#160;2000</xref>, qualifying physicians can obtain a waiver from the special registration requirements described in NATA (<xref rid="bib0089" ref-type="bibr">NATA,&#160;1974</xref>), can treat OUD with Schedule III, IV, and V opioid medications that have been specifically approved by the US Food and Drug Administration (FDA) for that indication, and can prescribe/dispense these medications in treatment settings other than licensed OTPs, including office-based practices.</p><p id="para0006">On July 22, 2016, President Obama signed&#160;S. 524, the Comprehensive Addiction and Recovery Act of 2016 (CARA) into law. CARA was enacted to address prevention, treatment, recovery support, criminal justice reform, overdose reversal, and law enforcement (<xref rid="bib0018" ref-type="bibr">CARA,&#160;2016</xref>). CARA and the Office of National Drug Control Policy (ONDCP) Reauthorization Act (<xref rid="bib0094" ref-type="bibr">ONDCP Reauthorization Act of 2006, 2006</xref>) also amended Section 303(g)(2) of the Controlled Substances Act (21 USC 823(g)(2)) to increase, under certain conditions and restrictions, the total number of patients a prescriber can treat with buprenorphine from 30 to 100. Most recently, President Biden signed a multipart appropriations bill on December 29, 2022 that included the Mainstreaming Addiction Treatment (MAT) Act (H.R. 1384/S. 445) which eliminates the federal &#8220;x-waiver&#8221; for prescribers of buprenorphine for OUD. The MAT Act holds promise to expand access to buprenorphine treatment for people with OUD and helps bring OUD treatment further into the mainstream of health care.</p><p id="para0007">Although empirical evidence supporting the effectiveness of medications for OUD (MOUD), particularly methadone or buprenorphine, as the gold-standard for OUD treatment is widely recognized, MOUD is strikingly underutilized. A recent study (<xref rid="bib0100" ref-type="bibr">Ronquest&#160;et&#160;al., 2018</xref>) conducted in the US examined patients with OUD who initiated buprenorphine treatment and were followed for 12 months. It was found that, indexed to each patient's earliest outpatient pharmacy claim for buprenorphine, &#8216;adherence&#8217; to buprenorphine treatment &#8211; defined as the proportion of days covered with buprenorphine being &#8805;0.80 &#8211; was associated with reduced odds of return to opioid use and reduced medical costs. However, recent adjusted estimates suggest past-year OUD affected 7631,804 individuals in the US in 2019 (2773 per 100,000 adults 12 +), relative to only 1023,959 individuals who received MOUD (365 per 100,000 adults 12 +). These data suggest that approximately 86.6% of individuals with OUD nationwide who may benefit from MOUD treatment do not receive it (<xref rid="bib0066" ref-type="bibr">Krawczyk&#160;et&#160;al., 2022</xref>). Many factors may contribute to suboptimal MOUD use including shortage of MOUD treatment providers and programs, especially in remote and rural areas (<xref rid="bib0049" ref-type="bibr">Haffajee&#160;et&#160;al., 2019</xref>; <xref rid="bib0069" ref-type="bibr">Langabeer&#160;et&#160;al., 2019</xref>), waivered providers not prescribing at all or to their maximum capacity (<xref rid="bib0025" ref-type="bibr">Duncan&#160;et&#160;al., 2020</xref>; <xref rid="bib0065" ref-type="bibr">Krawczyk&#160;et&#160;al., 2021</xref>), stigma harbored and communicated by providers that undermines patients&#8217; engagement in treatment, and lack of integrated systems of care (<xref rid="bib0059" ref-type="bibr">Jones&#160;et&#160;al., 2021</xref>).</p><p id="para0008">To address the disparity between treatment availability and patients&#8217; access to treatment, on September 20, 2018, the US Surgeon General released Facing Addiction in America: The Surgeon General's Spotlight on Opioids (<xref rid="bib0115" ref-type="bibr">US&#160;HHS,&#160;2018</xref>), which called for a cultural shift in the way Americans talk about the opioid crisis and recommended actions to prevent and treat opioid misuse and promote recovery. On September 28, 2018, the House of Representatives approved comprehensive opioid legislation (H.R. 6, the &#8220;Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act,&#8221; also known as the &#8220;SUPPORT for Patients and Communities Act&#8221;). President Trump signed this&#160;comprehensive opioid&#160;bill&#160;into law on October 24, 2018 (<xref rid="bib0112" ref-type="bibr">SUPPORT,&#160;2018</xref>). The law included provisions specific to buprenorphine prescribing, including but not limited to the following: (1) making permanent the prescribing authority for physician assistants and nurse practitioners; (2) permitting clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to become qualifying practitioners for a 5-year period (from October 1, 2018 to October 1, 2023); (3) allowing pharmacies to deliver implantable or injectable medications to treat substance use disorders directly to health care providers and allowing for administration by non-waivered healthcare providers; (4) allowing waivered practitioners to immediately treat 100 patients at a time if the practitioner is board certified in addiction medicine or addiction psychiatry or if the practitioner provides MOUD in a qualified practice setting, (5) authorizing clinical nurse specialists, certified nurse midwives, and certified registered nurse anesthetists to prescribe MOUD for 5 years, and (6) enabling qualified physicians to prescribe MOUD for up to 275 patients. If a non-physician practitioner (e.g., nurse) works in a state that requires he/she prescribes under the supervision of, or in collaboration with, a qualified physician, the physician does not need a waiver, but needs to be qualified to apply for it.</p></sec><sec id="sec0002"><label>2</label><title>The early stages of a partnership between the US government and private industry</title><p id="para0009">In the 1960s, Reckitt &amp; Colman (R&amp;C) based in Kingston upon Hull in the East Riding of Yorkshire, England, had a product called Codis&#174;, which was a formulation containing aspirin and codeine. That product was the fulcrum for an opioid discovery initiative aimed at identifying an &#8220;improvement on codeine&#8221; with fewer side effects (e.g., constipation, respiratory depression, abuse liability) than other opioids (<xref rid="bib0073" ref-type="bibr">Lewis,&#160;1999</xref>). The lead candidate molecule that resulted from this development program was buprenorphine (M6029) in 1966, the first of many milestones in its scientific evolution (see <xref rid="fig0001" ref-type="fig">Fig.&#160;1</xref>, Panel A). Two chemists who played an important role in the buprenorphine development program were John Lewis and Kenneth Bentley. Dr. Lewis had first met Dr. Bentley in 1950 when he was a freshman at Oxford; he was later a doctoral student of the Nobel prize-winning chemist, Sir Robert Robinson. Dr. Bentley, described as the father of a class of semi-synthetic opioids also known as the &#8220;Bentley compounds,&#8221; was a postdoctoral scientist at Oxford when Dr. Lewis did graduate work there. Dr. Bentley went on to work for MacFarlan Smith in Edinburgh (the main British producer of opium alkaloids at the time). In 1958, MacFarlan Smith entered into a joint venture with R&amp;C to develop over-the-counter analgesics. In 1963, R&amp;C took over the joint project and in 1965 Dr. Lewis joined the company. R&amp;C subsequently provided buprenorphine throughout the 1970s to scientists at the Addiction Research Center (ARC), then located in Lexington, Kentucky (<xref rid="bib0014" ref-type="bibr">Campbell&#160;and Lovell,&#160;2012</xref>).<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Key milestones in the development of buprenorphine for the treatment of opioid dependence or opioid use disorder*: Pre-regulatory (Panel A) and post-regulatory (Panel B) approval milestones.</p><p>*Opioid use disorder is the current terminology.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="para0010">In 1972, Dr. Lewis presented the pharmacological profile of buprenorphine at the annual meeting of the Committee on Problems of Drug Dependence (CPDD). In 1977, R&amp;C registered Temgesic Injection&#174; (0.3&#160;mg/mL buprenorphine) in the United Kingdom (UK) for treating moderate to severe pain; it was packaged in 1-mL terminally autoclaved glass ampoules (<xref rid="bib0028" ref-type="bibr">emc,&#160;2020</xref>). Soon thereafter in 1978, Dr. Donald Jasinski and colleagues at the ARC described the potential of buprenorphine to be used as a pharmacotherapeutic approach for &#8220;narcotic addiction&#8221; in a paper published in the <italic toggle="yes">Archives of General Psychiatry</italic> (<xref rid="bib0056" ref-type="bibr">Jasinski&#160;et&#160;al., 1978</xref>). Study participants were healthy, male federal prisoner volunteers with histories of recurrent addiction to narcotics. The studies were conducted over a 1-year period beginning in June 1975. The review of the protocol and informed consent procedures and the opportunity to leave the study without prejudice were in accord with existing Department of Health, Education, and Welfare regulations for the protection of study participants in biomedical and behavioral research.</p><p id="para0011">In 1979, after a nationwide ban on the use of federal prisoners as research participants made it difficult to find participants for clinical studies in Kentucky (<xref rid="bib0064" ref-type="bibr">Kolberg,&#160;1995</xref>), the National Institute on Drug Abuse (NIDA) moved the ARC clinical research program under the direction of Dr. Jasinski to what was then the Francis Scott Key Medical Center, currently the Johns Hopkins University (JHU) Bayview medical campus in Baltimore, Maryland. That move facilitated collaborations with the JHU Behavioral Pharmacology Research Unit headed by Dr. George Bigelow, including a comparative study of buprenorphine and methadone (<xref rid="bib0007" ref-type="bibr">Bickel&#160;et&#160;al., 1988a</xref>) and a dose-ranging study of buprenorphine incorporating an opioid challenge procedure (<xref rid="bib0008" ref-type="bibr">Bickel&#160;et&#160;al., 1988b</xref>). Dr. Rolley &#8220;Ed&#8221; Johnson, the pharmacist who had prepared buprenorphine formulations for Dr. Jasinski's studies in Lexington, assisted Dr. Jasinski in moving the clinical research program from Lexington to Baltimore. While working at the ARC, currently the NIDA Intramural Research Program, Dr. Johnson was lead investigator on numerous studies evaluating the efficacy and safety of buprenorphine. An intense yet informal relationship between R&amp;C and the ARC would facilitate research that antedated a Cooperative Research and Development Agreement (CRADA). R&amp;C continued to supply buprenorphine to NIDA for distribution to its grantees who performed preclinical and clinical studies with buprenorphine. During that period, in February 1983, CPDD held a symposium (<xref rid="bib0072" ref-type="bibr">Lewis,&#160;1985</xref>) that included an important review of buprenorphine presented by Dr. Lewis.</p><p id="para0012">In 1989, the US Congress mandated that a Medications Development Program be established at NIDA. A Medications Development Division (MDD) was created to develop close working relationships between academia, the pharmaceutical industry, and government agencies, including the FDA (<xref rid="bib0123" ref-type="bibr">Vocci&#160;and Ling,&#160;2005</xref>). On July 16 and 17, 1990, Dr. Charles R. Schuster, the NIDA Director, convened a technical review meeting on the status of buprenorphine as a potential treatment for opioid dependence. NIDA grantees and researchers presented and discussed the results from clinical pharmacology studies and clinical trials involving buprenorphine used for opioid detoxification or maintenance treatment. Perhaps the most compelling presentation from this body of research was a preliminary report of a study conducted by Johnson and colleagues that was later published in <italic toggle="yes">JAMA</italic> (<xref rid="bib0057" ref-type="bibr">Johnson&#160;et&#160;al., 1992</xref>). These investigators reported that the group of opioid-dependent, heroin-using participants randomized to 8&#160;mg/day sublingual buprenorphine solution used significantly less opioids and had better retention than the group randomized to 20&#160;mg of oral methadone, and that buprenorphine was as effective as methadone 60&#160;mg/day. This study (<italic toggle="yes">N</italic>&#160;=&#160;162; 70% male; outcomes by sex not reported) was ultimately one of three pivotal clinical trials that the FDA relied on to support the efficacy and safety of buprenorphine for the treatment of opioid dependence.</p></sec><sec id="sec0003"><label>3</label><title>The development of buprenorphine as a drug product</title><p id="para0013">As a result of Dr. Schuster's technical review meeting, a project team was formed in September 1990 to focus on the development of an inter-agency agreement (3Y01-DA-30,011&#8211;04) with the Department of Veterans Affairs Cooperative Studies Program (VACSP). The VACSP required that a VA investigator be involved in clinical studies run under the NIDA/VACSP agreement. Dr. Charles O'Brien agreed to fill that role and set up a medications development group at the Philadelphia VA that worked closely with NIDA and the VACSP Data Coordinating Center at Perry Point, Maryland and the VACSP Clinical Research Pharmacy Coordinating Center in Albuquerque, New Mexico. In 1995, Dr. Paul Fudala became the principal investigator of that NIDA/VACSP agreement and continued in that role until 2005. The VACSP collaborated with NIDA on two of the three pivotal studies that helped secure FDA approval of buprenorphine (SUBUTEX&#174;; Reckitt Benckiser Healthcare (UK) Ltd.; Hull, UK) and buprenorphine/naloxone (SUBOXONE&#174;; Reckitt Benckiser Healthcare (UK) Ltd.; Hull, UK) tablets for the treatment of opioid dependence in 2002. The clinical development program was also influenced by work performed by NIDA grantees. For example, Dr. Walter Ling had conducted a large, multisite study of buprenorphine in an opioid-dependent population, and was awarded a supplement to expand the size of the study. NIDA also applied VACSP and other resources to the development and execution of that trial, which explored a range of dosages of buprenorphine as recommended by the technical review meeting participants. The multisite study of opioid-dependent, heroin-using individuals (<italic toggle="yes">N</italic>&#160;=&#160;736; 68% male; outcomes by sex not reported) evaluated the safety and efficacy of an 8&#160;mg per day dosage of buprenorphine (given as a sublingual solution) in the maintenance treatment of heroin-dependent individuals compared to a 1&#160;mg per day dosage over a 16-week treatment period (<xref rid="bib0076" ref-type="bibr">Ling&#160;et&#160;al., 1998</xref>). As a secondary objective, outcomes were determined concurrently for participants treated with dosages of 4&#160;mg and 16&#160;mg per day. Outcomes in the 8&#160;mg group were significantly better than in the 1&#160;mg group on the four domains of retention in treatment, illicit opioid use, opioid craving, and global ratings by participants and staff. In addition to the <xref rid="bib0057" ref-type="bibr">Johnson&#160;et&#160;al., (1992)</xref> study, these research efforts informed the likely effective dosage range of buprenorphine for opioid-dependence treatment.</p><p id="para0014">Given that the two previous pivotal studies had been performed with a buprenorphine solution, the FDA advised that a single study of the buprenorphine mono and combination tablets as well as a control (placebo) group would be needed to establish the efficacy of the tablet formulations. That study (<xref rid="bib0033" ref-type="bibr">Fudala&#160;et&#160;al., 2003</xref>), led by principal investigators Drs. Paul Fudala and T. Peter Bridge (representing the VACSP and NIDA, respectively), would be the third study to be considered pivotal with regard to the eventual FDA approval of SUBUTEX&#174; and SUBOXONE&#174; tablets and the only pivotal study that was conducted with tablet formulations rather than a buprenorphine sublingual solution. During the first 4-week part of the study, 326 participants were randomized to daily office-based treatment with buprenorphine (16&#160;mg), buprenorphine/naloxone (16&#160;mg/4&#160;mg) or placebo; 323 (65% male; outcomes by sex not reported) received at least one dose of study medication. Those receiving buprenorphine were inducted with the buprenorphine mono product (8&#160;mg on day 1 and 16&#160;mg on day 2); those randomized to receive buprenorphine/naloxone received buprenorphine on days 1 and 2 and were switched on day 3 to 16&#160;mg/4&#160;mg buprenorphine/naloxone. Participants randomized to the placebo group were given one placebo tablet on day 1 and 2 tablets on day 2 and all dosing days thereafter. Participants completing the 4-week efficacy study were given the opportunity to continue with the second 48-week phase of open-label buprenorphine/naloxone treatment so that additional safety data could be collected. To ensure collection of a sufficient amount of safety data, a separate 52-week open-label safety study at four sites was conducted to assess buprenorphine/naloxone doses of up to 24&#160;mg/6&#160;mg per day.</p><p id="para0015">The study data and safety monitoring board and the institutional review board recommended terminating the double-blind portion of the study early because both active treatments (buprenorphine 16&#160;mg/naloxone 4&#160;mg and buprenorphine 16&#160;mg) were found to have greater efficacy than placebo. Results showed that participants in the buprenorphine and buprenorphine/naloxone groups demonstrated significantly less opioid use and craving compared to those who received placebo. A total of 461 participants received open-label treatment using flexible dosing up to buprenorphine 24&#160;mg/naloxone 6&#160;mg per day; 268 of those had participated in the double-blind portion of the study. The percentages of urine samples negative for opioids ranged from 35% to 67%. There were no unexpected safety issues during the study.</p></sec><sec id="sec0004"><label>4</label><title>The cooperative research and development agreement (CRADA) between NIDA and R&amp;C</title><p id="para0016">During the conduct of the Ling et&#160;al. multicenter study, NIDA and R&amp;C developed the CRADA entitled <italic toggle="yes">Development of Buprenorphine Products for the Treatment of Opioid Dependence,</italic> which was ultimately signed in April 1994 with Dr. Chris Chapleo from R&amp;C as the principal investigator. The goal of the CRADA was, &#8220;<italic toggle="yes">To cooperatively design and perform the necessary research and cooperatively analyze the data generated to develop and attempt to gain NDA approval of two buprenorphine products for the treatment of opiate dependence.</italic>&#8221; The first product, a mono substance would be administered &#8220;on premises&#8221; in clinics registered pursuant to NATA requirements (<xref rid="bib0089" ref-type="bibr">NATA,&#160;1974</xref>). The second development product, buprenorphine combined with naloxone, would be attempted under this CRADA as a potential &#8220;take-home&#8221; medication. The goal was that such a product, if successfully developed, would &#8220;minimize the likelihood of diversion for illicit use by opiate-dependent persons.&#8221; Naloxone was chosen instead of naltrexone after discussions with the FDA. The FDA opined that misuse of a buprenorphine/naloxone product could precipitate withdrawal in a highly physically-dependent user. FDA was concerned that the misuse of a buprenorphine/naltrexone product would produce a prolonged withdrawal that would need to be treated in hospital emergency departments.</p><p id="para0017">Dr. Frank Vocci, a pharmacologist who had joined NIDA in 1989 from the FDA and who later became Director of the MDD, played a critical role in the CRADA development. Duration of the CRADA was 5 years, during which time NIDA and R&amp;C had the following joint responsibilities: (1) develop buprenorphine and buprenorphine/naloxone combination formulations suitable for sublingual use as detoxification and maintenance agents in the treatment of opioid dependence; and (2) submit an NDA to the FDA for suitable opioid dependence treatment products. R&amp;C bought back its US distribution rights but had to set up a US company (R&amp;C Pharmaceuticals, Inc.), as well as develop an infrastructure (secure warehouse services, import permits, etc.) before entering into the CRADA. The CRADA was subsequently amended four times after its initial signing for various reasons, including to complete requirements related to the NDA and to perform a &#8220;best practices&#8221; study. The CRADA ended on October 28, 2003.</p></sec><sec id="sec0005"><label>5</label><title>Key clinical pharmacology studies within the scope of the CRADA</title><p id="para0018">A bridging bioavailability/PK study of liquid and solid mono products was necessary to establish the bioavailability of the solid dosage form in reference to the liquid. This was required for future clinical trials to link to previous work, thus allowing the FDA to use relevant studies completed with the liquid dosage form to be considered as &#8220;pivotal&#8221; studies for approval.</p><p id="para0019">The bioavailability of sublingual buprenorphine was determined by comparing plasma levels obtained following a 2-mg sublingual dose to those found after a 1-mg intravenous (IV) dose in 6 research volunteers (<xref rid="bib0085" ref-type="bibr">Mendelson&#160;et&#160;al., 1997a</xref>). The absolute bioavailability of sublingual buprenorphine was approximately 29%. The relative bioavailability of the solution to the tablet was also assessed. An 8-mg tablet dose was compared to a 7.7-mg sublingual solution dose, and relative bioavailability of the tablet was found to be approximately 50% (<xref rid="bib0092" ref-type="bibr">Nath&#160;et&#160;al., 1999</xref>; <xref rid="bib0103" ref-type="bibr">Schuh&#160;and Johanson,&#160;1999</xref>).</p><p id="para0020">Several clinical pharmacology studies were also conducted to determine the appropriate dose ratio of buprenorphine to naloxone. Two studies were performed in morphine-stabilized (15&#160;mg given intramuscularly [IM] 4 times daily) opioid-dependent participants. <xref rid="bib0034" ref-type="bibr">Fudala&#160;et&#160;al., (1998)</xref> gave IV injections of placebo, morphine 15&#160;mg, buprenorphine 2&#160;mg, buprenorphine 2&#160;mg/naloxone 0.5&#160;mg, and naloxone 0.5&#160;mg at 48- to 72-hour intervals. Both naloxone and buprenorphine/naloxone produced significant opioid-withdrawal effects compared to placebo. The authors suggested that the addition of naloxone to buprenorphine in a 4:1 ratio would limit the potential for IV abuse in opioid-dependent individuals. <xref rid="bib0087" ref-type="bibr">Mendelson&#160;et&#160;al., (1999)</xref> also stabilized opioid-dependent participants on 60&#160;mg/day morphine given IM as 4 divided doses. The following challenges were given IV utilizing a double-blind, placebo-controlled, balanced crossover design: buprenorphine 2&#160;mg, buprenorphine 2&#160;mg in combination with naloxone at doses of 0.25&#160;mg (8:1), 0.5&#160;mg (4:1), and 1&#160;mg (2:1), morphine 15&#160;mg, and placebo. The authors reported that the 4:1 and 2:1 ratios of buprenorphine/naloxone produced moderate to high withdrawal and reduced the pleasurable effects of buprenorphine as well as its estimated street value. The effects of the administration of buprenorphine in combination with naloxone to methadone-maintained patients (40&#8211;60&#160;mg/day) were also determined (<xref rid="bib0086" ref-type="bibr">Mendelson&#160;et&#160;al., 1997b</xref>). Naloxone (0.1&#160;mg) produced severe opioid withdrawal. The combination of buprenorphine/naloxone (0.2&#160;mg/0.1&#160;mg) precipitated a withdrawal syndrome at least as severe as the one precipitated by naloxone.</p><p id="para0021">The <xref rid="bib0034" ref-type="bibr">Fudala&#160;et&#160;al., (1998)</xref> and <xref rid="bib0087" ref-type="bibr">Mendelson&#160;et&#160;al., (1999)</xref> studies clearly established that 4:1 buprenorphine/naloxone was the optimal dose ratio. Therefore, the decision was made to develop 2-mg and 8-mg buprenorphine tablets and 2-mg/0.5-mg and 8-mg/2-mg buprenorphine/naloxone tablets.</p></sec><sec id="sec0006"><label>5</label><title>The regulatory approval of buprenorphine for the treatment of OUD</title><p id="para0022"><xref rid="fig0001" ref-type="fig">Fig.&#160;1</xref>, Panel B illustrates key milestones toward regulatory approval of buprenorphine formulations.</p><sec id="sec0007"><label>5.1</label><title>Buprenorphine and buprenorphine/naloxone sublingual tablet</title><p id="para0023">The year after the CRADA was signed, a contaminated blood transfusion scandal and the AIDS epidemic in France incentivized the French regulatory authorities to approve buprenorphine for the treatment of opioid dependence, partly from a harm-reduction perspective with regard to decreasing the risks of HIV and hepatitis infections (<xref rid="bib0014" ref-type="bibr">Campbell&#160;and Lovell,&#160;2012</xref>; <xref rid="bib0031" ref-type="bibr">Feroni&#160;and Lovell,&#160;2007</xref>). SUBUTEX&#174; first received marketing approval in France in July 1995 and was subsequently launched there in February 1996 by Schering-Plough under license from R&amp;C. Over the next several years, the studies required for the NDA submissions were completed and NDAs for the buprenorphine and buprenorphine/naloxone tablet formulations were finalized and submitted to the FDA. Buprenorphine (SUBUTEX&#174;) and buprenorphine/naloxone (SUBOXONE&#174;) tablets for sublingual administration were approved for the treatment of opioid dependence in the US on October 8, 2002.</p></sec><sec id="sec0008"><label>5.2</label><title>Buprenorphine/naloxone sublingual film</title><p id="para0024">In 2007, Reckitt Benckiser Pharmaceuticals, Inc. (RBP), later to become Indivior Inc., established a partnership with MonoSol Rx (Monosol) (now Aquestive Therapeutics) to develop SUBOXONE&#174; sublingual film by leveraging the MonoSol Rx PharmFilm&#174; technology (Aquestive; Warren; New Jersey). On August 30, 2010, the FDA approved SUBOXONE&#174; sublingual film. Both the SUBUTEX&#174; tablets and SUBOXONE&#174; tablets (no longer marketed in the US) and film are listed on Schedule III of the US Controlled Substances Act (1970) and therefore may be used to treat opioid dependence under <xref rid="bib0023" ref-type="bibr">DATA&#160;2000</xref> (details can be found in Title 21 US Code (USC) Controlled Substances Act). Since 2010, several transmucosal products have been approved by the FDA for sublingual or buccal use; these include ZUBSOLV&#174; (buprenorphine/naloxone) sublingual tablet from Orexo US Inc., Morristown, New Jersey (FDA approval July 3, 2013) (<xref rid="bib0116" ref-type="bibr">US&#160;FDA,&#160;n.d.a</xref>), BUNAVAIL&#174; (buprenorphine/naloxone) buccal film from BioDelivery Sciences International Ltd, Raleigh, North Carolina (FDA approval June 6, 2014; now discontinued) (<xref rid="bib0117" ref-type="bibr">US&#160;FDA,&#160;n.d.b</xref>), and CASSIPA&#174; (buprenorphine/naloxone) sublingual film from Teva Pharmaceuticals USA, Fairfield, New Jersey (FDA approval September 7, 2018; now discontinued) (<xref rid="bib0118" ref-type="bibr">US&#160;FDA,&#160;n.d.c</xref>) Numerous generic versions of transmucosal buprenorphine/naloxone products have also been approved by the FDA for sublingual or buccal use. As indicated in the FDA Orange Book (<xref rid="bib0122" ref-type="bibr">US&#160;FDA,&#160;2022</xref>), none of the buprenorphine products described in this paper were discontinued or withdrawn for safety or effectiveness reasons (discontinuation dates not indicated).</p></sec><sec id="sec0009"><label>5.3</label><title>Long-acting formulations of buprenorphine</title><p id="para0025">Concerns about non-adherence to daily medication treatment (potentially leading to withdrawal, craving, and return to opioid use) and the diversion and nonmedical use of transmucosal buprenorphine products served as an impetus for the development of long-acting formulations of buprenorphine.</p><sec id="sec0010"><label>5.3.1</label><title>PROBUPHINE&#174; (buprenorphine) implant for subdermal administration CIII</title><p id="para0026">The first long-acting formulation of buprenorphine to be approved by the FDA (in 2018) was PROBUPHINE&#174;, a surgical implant (Braeburn Pharmaceuticals, Inc., Plymouth Meeting, Pennsylvania). This implant is a solid polymer matrix (ProNeura&#8482; technology from Titan Pharmaceuticals Inc., New York, New York) consisting of ethylene vinyl acetate and buprenorphine designed to deliver stable buprenorphine concentrations (via continuous dissolution of the matrix) over 6 months. Four cylindrical, matchstick-sized rods (26&#160;mm X 2.5&#160;mm), each containing 74.2&#160;mg of buprenorphine (equivalent to 80&#160;mg of buprenorphine HCl; total buprenorphine dose, 296.8&#160;mg for 4 rods), are implanted subdermally inside the upper arm under local anesthesia. The implants do not biodegrade and must be removed after 6 months. If the patient chooses to continue treatment, implants are then placed in the alternate arm. Healthcare providers must successfully complete a live training program on the insertion and removal procedures and become certified in the PROBUPHINE&#174; Risk Evaluation and Mitigation Strategy (REMS) program prior to inserting or prescribing PROBUPHINE&#174; implants. As a prerequisite for participating in the live training program leading to certification, the healthcare provider must have performed at least one qualifying surgical procedure in the last 3 months. Qualifying procedures are those performed under local anesthesia using aseptic technique and include, at a minimum, making skin incisions, or placing sutures (<xref rid="bib0114" ref-type="bibr">Titan&#160;Pharmaceuticals,&#160;Inc., 2022</xref>).</p><p id="para0027">In an open-label study conducted in opioid-dependent individuals who had been receiving sublingual buprenorphine prior to it being discontinued, participants were treated with either 2 or 4 PROBUPHINE&#174; rods (dose per rod, 90&#160;mg) (<xref rid="bib0127" ref-type="bibr">White&#160;et&#160;al., 2009</xref>). This open-label study was followed by a placebo-controlled, randomized trial that evaluated the efficacy of PROBUPHINE&#174; in combination with individual drug counseling (<xref rid="bib0075" ref-type="bibr">Ling&#160;et&#160;al., 2010</xref>). Individuals diagnosed with opioid dependence were randomized (2:1) to receive PROBUPHINE&#174; (<italic toggle="yes">n</italic>&#160;=&#160;108) or placebo (<italic toggle="yes">n</italic>&#160;=&#160;55). Participants could also receive sublingual buprenorphine if needed. The primary endpoint was the percentage of urine samples negative for illicit opioids for weeks 1 to 16 and weeks 17 to 24. Participants who received active buprenorphine implants had a mean percentage of opioid-negative urine samples of 40.4% compared to 28.3% for those who received placebo implants. The percentage of participants who completed the study in the active group was more than twice that of the placebo group (65.7% vs 30.9%). Implant site reactions were the most common adverse events, experienced by 56.5% and 52.7% of the active and placebo groups, respectively. Subsequently, a phase III, 24-week, randomized, double-blind, double-dummy trial found that 85.7% of participants in the active PROBUPHINE&#174; group (placebo sublingual tablets) maintained opioid abstinence relative to 71.9% of those in the sublingual tablet group (placebo PROBUPHINE&#174;) (<xref rid="bib0101" ref-type="bibr">Rosenthal&#160;et&#160;al., 2016</xref>). Implant-related adverse events occurred in 23% of the active implant group and 13.5% of the active sublingual group, respectively. It is noteworthy that unblinded supplemental sublingual buprenorphine use was allowed as needed during this study and that four buprenorphine implants (totaling 296.8&#160;mg buprenorphine) were expected to yield plasma buprenorphine concentrations (0.5&#8211;1.0&#160;ng/mL) at a range comparable with 8-mg/day or less of sublingual buprenorphine. Furthermore, study participants were clinically stable prior to being randomized to a study treatment, having received sublingual buprenorphine for at least 24 weeks at a stable dosage of 8&#160;mg/day or less, and having shown no evidence of opioid withdrawal or illicit opioid-positive urine samples for at least 90 days prior to study entry. Relatedly, the PROBUPHINE&#174; prescribing information indicates that PROBUPHINE&#174; is indicated for maintenance treatment of opioid dependence in patients who have achieved sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8&#160;mg/day of SUBUTEX&#174; or SUBOXONE&#174; sublingual tablet or generic equivalent). Additionally, patients should not be tapered to a lower dose for the sole purpose of transitioning to PROBUPHINE&#174;. Following a Psychopharmacologic Drugs Advisory Committee Meeting held on January 12, 2016 (<xref rid="bib0015" ref-type="bibr">Casetext,&#160;2015</xref>), PROBUPHINE&#174; received FDA approval on May 26, 2016. On October 16, 2020, Titan Pharmaceuticals Inc. announced its decision to discontinue sales of PROBUPHINE&#174; for OUD in the US as part of its restructuring plan.</p></sec><sec id="sec0011"><label>5.3.2</label><title>SUBLOCADE&#174; (buprenorphine extended-release) injection, for subcutaneous use (CIII)</title><p id="para0028">In 2009, Indivior initiated a new development program (RBP-6000, BUP-XR, or SUBLOCADE&#174;, Indivior Inc., North Chesterfield, Virginia) aimed at identifying safe and effective dosing regimens of a buprenorphine depot product, dissolved in a biocompatible solvent. When the liquid polymer system is injected into the body using a conventional syringe with a needle, it solidifies upon contact with aqueous body fluids to form a solid implant. When a drug (in this case buprenorphine) is incorporated into the polymer solution, it becomes incorporated within the polymer matrix as it solidifies and is slowly released as the polymer biodegrades.</p><p id="para0029">The SUBLOCADE&#174; development program utilized knowledge of the relationship between buprenorphine plasma levels, whole-brain mu-opioid receptor occupancy (MOR), and the key clinical pharmacodynamic (PD) effects of withdrawal suppression and opioid blockade, based on sublingual dosing studies. The primary hypothesis based on preliminary observations in heroin-dependent individuals was that at least 70% brain MOR occupancy by buprenorphine is required to block the subjective drug-liking effects (i.e., to provide opioid blockade) of opioid agonists. Analysis of MOR occupancy (measured with [<sup>11</sup>C]carfentanil positron emission tomography [PET] imaging) and buprenorphine plasma concentrations suggested that opioid blockade would require buprenorphine plasma concentrations &#8805;2&#160;ng/mL (<xref rid="bib0041" ref-type="bibr">Greenwald&#160;et&#160;al., 2003</xref>). A subsequent study showed that the duration of PD action (estimated by suppression of opioid withdrawal and craving, and blockade of high-dose hydromorphone agonist effects) during 3-day discontinuation following daily sublingual buprenorphine (16&#160;mg/day) dosing decreased over time and was highly correlated with plasma concentrations of buprenorphine and MOR occupancy (<xref rid="bib0042" ref-type="bibr">Greenwald&#160;et&#160;al., 2007</xref>). Opioid agonist effects produced by hydromorphone were blocked at 4&#160;h after sublingual buprenorphine 16&#160;mg, but returned over time, together with withdrawal symptoms and craving, as plasma concentrations of buprenorphine and MOR occupancy decreased.</p><p id="para0030">The clinical development plan for SUBLOCADE&#174; consisted of a first-in-human, single-dose (20&#160;mg) study, a single ascending-dose study (50, 100 and 200&#160;mg), and a multiple-dose study (50, 100, 200, and 300&#160;mg). Several population PK models were developed using data from opioid-dependent participants who received subcutaneous doses of SUBLOCADE&#174;. In addition, PK/PD models were developed using MOR occupancy data to predict the clinical efficacy of SUBLOCADE&#174; after repeated doses. Results of the population PK analyses jointly with the predicted level of MOR occupancy confirmed earlier findings of a non-linear relation between buprenorphine plasma concentrations and MOR occupancy (<xref rid="bib0039" ref-type="bibr">Greenwald,&#160;2006</xref>), and provided quantitative criteria for the clinical dose selection for SUBLOCADE&#174;; a dose of 300&#160;mg every 28 days was deemed appropriate to immediately achieve effective plasma concentrations of buprenorphine after the first subcutaneous injection and to maintain these effective levels of exposure during chronic treatment (Nasser et&#160;al., 2007; <xref rid="bib0067" ref-type="bibr">Laffont&#160;et&#160;al., 2016</xref>).</p><p id="para0031">An opioid blockade study (<xref rid="bib0090" ref-type="bibr">Nasser&#160;et&#160;al., 2016</xref>; <xref rid="bib0053" ref-type="bibr">Indivior&#160;Inc., 2022</xref>) was then conducted to test the original &#8220;blockade of subjective opioid effects&#8221; hypothesis. Stabilization doses of sublingual buprenorphine (considered collectively and ranging from 8 to 24&#160;mg across participants) prior to injection of SUBLOCADE&#174; failed to fully block drug liking of hydromorphone 18&#160;mg IM. In contrast, complete hydromorphone blockade of drug-liking effects was achieved by SUBLOCADE&#174; for both hydromorphone doses (6 and 18&#160;mg) during each week of testing for the 4 weeks after the first dose of SUBLOCADE&#174; and also throughout the 8 weeks following the second SUBLOCADE&#174; injection. In a [<sup>11</sup>C]carfentanil PET study of SUBLOCADE&#174; in two participants with OUD (one receiving 200-mg injections and one receiving 300-mg injections), 75% to 92% occupancy of whole-brain MOR was maintained for 28 days following the last dose under steady-state conditions. These data strongly supported the hypothesis that the minimum threshold plasma concentration of buprenorphine needed to effectively block the subjective drug-liking effects of a full opioid agonist such as hydromorphone was 2&#160;ng/mL, which translated into at least 70% MOR occupancy in the brain for the entire 1-month period. Analysis of a secondary outcome (drug vs. money choices) also found that hydromorphone-seeking behavior was significantly attenuated throughout the monthly interval. This measure is not often included in FDA qualifying trials; the finding was, therefore, encouraging for efficacy and reinforces the predictive validity of liking as an index of abuse potential.</p><p id="para0032">The efficacy and safety of SUBLOCADE&#174; was subsequently assessed in a phase III, randomized, double-blind, placebo-controlled, multicenter trial with two active dose regimens versus placebo (<italic toggle="yes">n</italic>&#160;=&#160;504) as well as in a phase III, open-label, long-term safety and tolerability trial with flexible dosing (<italic toggle="yes">n</italic>&#160;=&#160;669). SUBLOCADE&#174; was shown to produce significantly higher percentage abstinence and treatment success versus placebo; treatment outcomes were consistent across other efficacy endpoints including control of opioid craving and withdrawal symptoms (<xref rid="bib0051" ref-type="bibr">Haight&#160;et&#160;al., 2019</xref>). SUBLOCADE&#174; in combination with individual counseling was shown to be safe and well-tolerated and had higher medication satisfaction scores compared with participants who received placebo and individual counseling. Importantly, no compensatory non-opioid illicit drug use was observed with SUBLOCADE&#174; treatment. Exposure&#8211;response relationships among clinical endpoints and predicted whole-brain MOR occupancy confirmed that the overall probability of no illicit opioid use (i.e., abstinence) increased within the range of 70% to 90% MOR occupancy. The probability of zero craving also increased between 70% to 90% MOR occupancy. The results indicated that 4 monthly SUBLOCADE&#174; 100-mg doses following 2 initial doses of 300&#160;mg were associated with a mean average buprenorphine plasma concentration (<italic toggle="yes">C</italic><sub>avg</sub>) of 3.14&#160;ng/mL, which corresponded to 75% MOR occupancy. Additionally, the results indicated that 6 monthly doses of SUBLOCADE&#174; 300&#160;mg provided a buprenorphine mean plasma <italic toggle="yes">C</italic><sub>avg</sub> of 6.32&#160;ng/mL, which corresponded to 83% MOR occupancy. A recent analysis of phase II and phase III SUBLOCADE&#174; data employed an integrated PK/PK model to characterize buprenorphine exposure-response relationships. Buprenorphine plasma concentrations were modeled in relation to several key clinical endpoints (suppression of withdrawal and craving, and blockade of opioid liking and drug-seeking behavior). This analysis confirmed that concentrations in the 2&#8211;3&#160;ng/mL range are effective in producing broad clinical benefits on these measures (<xref rid="bib0068" ref-type="bibr">Laffont&#160;et&#160;al., 2022</xref>). This comprehensive analysis further identified several individual differences in these PK/PD relationships, including demographic, genetic, and social factors, which are an important topic of future study for optimizing outcomes.</p><p id="para0033">The long-term safety of SUBLOCADE&#174; was assessed in a phase III, open-label, multicenter study (<xref rid="bib0004" ref-type="bibr">Andorn&#160;et&#160;al., 2020</xref>) in adults with moderate or severe OUD. This study enrolled 257 participants from the previously-conducted placebo-controlled, double-blind phase III trial (rollover group) and 412 new participants who had not previously been treated with SUBLOCADE&#174; (<italic toggle="yes">de novo</italic> group). Overall, 66.8% of participants reported &gt;1 treatment-emergent adverse event (TEAE). Injection-site TEAEs (13.2% of participants) were mostly mild or moderate in severity. There were no clinically meaningful changes in safety assessments. The incidence of TEAEs, including injection-site TEAEs, were lower during the second 6 months of treatment versus the first 6 months (descriptive comparison of double-blind and open-label populations). The percentage of participants abstinent after 12 months of treatment was 61% in the rollover group and 75.8% in the <italic toggle="yes">de novo</italic> group. An additional 6-month, open-label, flexible-dose study (12 months&#160;+&#160;6 months for a total of 18 months) included 208 individuals who had completed the open-label phase III trial. Participants received an initial injection of SUBLOCADE&#174; 300&#160;mg and subsequent monthly 300-mg or 100-mg flexible doses. In the 6-month extension study, 90.4% were abstinent at the 18-month timepoint.</p><p id="para0034">SUBLOCADE&#174; was granted US Fast Track Designation on May 23, 2016. A pre-NDA meeting was held on December 14, 2016, which was followed by the NDA submission on May 30, 2017, and Prescription Drug User Fee Act (PDUFA) Priority Review designation on July 29, 2017. A joint advisory committee of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee was held on October 31, 2017, to discuss the efficacy, safety, and benefit-risk profile of SUBLOCADE&#174;. SUBLOCADE&#174; (buprenorphine extended-release injection for subcutaneous use [CIII]) was approved by the FDA on November 30, 2017, for the treatment of moderate to severe OUD in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of 7 days.</p><p id="para0035">Beyond clinical efficacy and safety, patient-reported outcomes (PRO) research was performed in accordance with the 2009 FDA Guidance for Industry, <italic toggle="yes">Patient-Reported Outcome Measures:&#160;Use in Medical Product Development to Support Labeling Claims</italic> (<xref rid="bib0120" ref-type="bibr">US&#160;FDA,&#160;2009</xref>) and the 2018 FDA Draft Guidance for Industry, <italic toggle="yes">Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment</italic> (<xref rid="bib0121" ref-type="bibr">US&#160;FDA,&#160;2020</xref>). In a 24-week, phase III, placebo-controlled study, participants receiving up to 6 monthly injections of SUBLOCADE&#174; 300/300&#160;mg (6&#160;&#215;&#160;300&#160;mg) and 300/100&#160;mg (2&#160;&#215;&#160;300&#160;mg then 4&#160;&#215;&#160;100&#160;mg) reported better health, increased medication satisfaction, increased employment, and decreased healthcare utilization compared with participants receiving placebo injections (<xref rid="bib0077" ref-type="bibr">Ling&#160;et&#160;al., 2019a</xref>). In an open-label study, participants who received SUBLOCADE&#174; for up to 12 months experienced improvement in health-related quality of life, health status, treatment effectiveness as assessed by the four domains (substance use, health, lifestyle, community) of the Treatment Effectiveness Assessment tool and high medication satisfaction (<xref rid="bib0078" ref-type="bibr">Ling&#160;et&#160;al., 2019b</xref>). These improvements were sustained over the study period, suggesting that SUBLOCADE&#174; facilitates long-term engagement of life activities that reflect recovery (<xref rid="bib0080" ref-type="bibr">Ling&#160;et&#160;al., 2020a</xref>). Finally, the RECOVER (Remission from Chronic Opioid Use&#8212;Studying Environmental and socioeconomic Factors on Recovery) study (<xref rid="bib0079" ref-type="bibr">Ling&#160;et&#160;al., 2019c</xref>) is an ongoing multisite, non-interventional cohort study examining the long-term recovery process among individuals with moderate to severe OUD who received one or more doses of SUBLOCADE&#174; in the phase III clinical trials. The objectives of the RECOVER study are to characterize periods of abstinence over a 24-month observational window, examine the clinical, environmental, and socioeconomic factors associated with periods of abstinence and return to opioid use, and understand the persistent effects of MOUD on clinical, humanistic, and economic outcomes in persons with OUD. The RECOVER data reported so far indicated that 75.3% of participants who had been treated with SUBLOCADE&#174; for 12 months achieved sustained illicit opioid-free weeks for the entire first 12 months versus only 24.1% of participants who were treated with SUBLOCADE&#174; for 0&#8211;2 months. Improved and sustained employment status and health-related quality of life over the 12-month observational period were also reported (<xref rid="bib0081" ref-type="bibr">Ling&#160;et&#160;al., 2020b</xref>). A recent study confirmed that up to 18 months after the last SUBLOCADE&#174; injection, RECOVER study participants largely retained or improved their outcomes over time, almost half of them reported sustained abstinence for the 18-month period, and those receiving a longer duration of SUBLOCADE&#174; had better outcomes (<xref rid="bib0009" ref-type="bibr">Boyett&#160;et&#160;al., 2022</xref>). A follow up study (<xref rid="bib0021" ref-type="bibr">Craft&#160;et&#160;al., 2022</xref>) at an average of 4.2 years post-treatment showed high levels of abstinence from opioids (74.1% in the past 7 days and 60% in the past 30 days). Furthermore, lower odds of opioid misuse were associated with improved quality of life and treatment effectiveness whereas higher odds of opioid misuse were associated with depression, psychological distress, opioid craving and withdrawal, and OUD symptoms (DSM 5 criteria) (<xref rid="bib0002" ref-type="bibr">American&#160;Psychiatric Association,&#160;2013</xref>).</p><p id="para0036">A recent 12-month prospective single-arm, multicenter, open-label trial in Australia, evaluated treatment retention, drug use, and other key outcomes following treatment with SUBLOCADE&#174; among people who were opioid-dependent with previous treatment experience (<xref rid="bib0030" ref-type="bibr">Farrell&#160;et&#160;al., 2022</xref>). Retention following SUBLOCADE&#174; treatment at 24 and 48 weeks was 86% and 75%, respectively. The odds of use of all illicit substances except for cannabis use decreased significantly with time retained in treatment. For example, the odds of heroin use in the past month decreased by 20% on average for every four weeks retained in treatment. Similarly, the odds of non-prescribed opioid use reduced by 17%, and the odds of past-month injecting drug use decreased by 26% for every 4 weeks retained in treatment. Concordance of self-reported substance use and urine test results were 94%, 92%, 93%, 88% and 100% for cannabis, amphetamines, opioids, benzodiazepines and cocaine respectively. The odds of being employed increased 58% for every 4 weeks people were retained in treatment. Significant increases in quality of life and treatment satisfaction were also observed together with a significant decline in pain and a significant reduction in the odds of moderate-severe depression for every 4 weeks retained in treatment.</p><p id="para0037">A pilot proof-of-concept study (<xref rid="bib0071" ref-type="bibr">Lee&#160;et&#160;al., 2021</xref>) also compared treatment retention following release from jail among adults receiving daily sublingual buprenorphine-naloxone vs. those receiving SUBLOCADE&#174; and showed that participants in the SUBLOCADE&#174; arm had fewer jail medical visits compared with daily sublingual medication administration. Community buprenorphine treatment retention at week 8 post-release was 69.2% in the SUBLOCADE&#174; group vs. 34.6% in the sublingual buprenorphine-naloxone group, and rates of opioid-negative urine tests were 55.3% in the SUBLOCADE&#174; group vs. 38.4% in the sublingual buprenorphine-naloxone group. There were no differences in rates of serious adverse events, no overdoses, and no deaths. Although preliminary, these findings suggest that monthly injectable extended-release buprenorphine is a useful OUD treatment option before and after release from jail. This conclusion is also supported by a recent series of in-depth qualitative interviews conducted among adult participants with OUD who were recently released from New York City jails and maintained on SUBLOCADE&#174; after switching from daily sublingual buprenorphine-naloxone (<xref rid="bib0017" ref-type="bibr">Cheng&#160;et&#160;al., 2022</xref>). SUBLOCADE&#174; treatment during jail-to-community reentry was perceived by participants as a favorable treatment approach to reduce their risk of opioid reuse, illicit activities, stigma associated with daily receipt of MOUD, and COVID-19 exposure. In another pilot study across two Veterans Health Administration outpatient clinics, 26 clinically complex patients at high risk for hospitalization and mortality received at least one SUBLOCADE injection between December 1, 2018 and April 1, 2020 (<xref rid="bib0020" ref-type="bibr">Cotton&#160;et&#160;al., 2022</xref>). Treatment retention was robust, 81% received more than 6 injections and 77% were maintained on the 300&#160;mg dosage strength. Treatment was also associated with reduction in Emergency Department (ED) visits (-48%), hospitalizations (-39%), days of hospitalization (-41%), non-prescribed opioid use, and homelessness.</p><p id="para0038">A recent clinical pharmacology study also assessed the competitive interaction of fentanyl and buprenorphine on respiratory depression (<xref rid="bib0088" ref-type="bibr">Moss&#160;et&#160;al., 2022</xref>). The study evaluated the ability of treatment-relevant plasma concentrations of buprenorphine to prevent respiratory depression as measured by minute ventilation (VE) and resultant apnea (cessation of breathing) induced by escalating doses of intravenous fentanyl. The maximum decrease in VE, induced by the highest dose of fentanyl, was nearly 60 percent less with a steady-state plasma buprenorphine concentration of 2.0&#160;ng/mL compared with placebo (33.7 percent vs 82.3 percent decrease in VE, respectively). The risk of experiencing apnea requiring verbal stimulation after fentanyl dosing was significantly lower with buprenorphine than with placebo. A follow-up publication further characterized buprenorphine-fentanyl interaction at the level of the MOR (<xref rid="bib0096" ref-type="bibr">Olofsen&#160;et&#160;al., 2022</xref>). The effects of escalating intravenous fentanyl doses within the 0.25&#8211;0.70&#160;mg/70&#160;kg range in chronic opioid users on isohypercapnic ventilation at 2&#8211;3 background doses of buprenorphine (target plasma concentrations range: 0.2&#8211;5&#160;ng/mL) were quantified using receptor association/dissociation models combined with biophase distribution models. The results showed that high doses of fentanyl caused pronounced respiratory depression and apnea. In contrast, when combined with fentanyl, buprenorphine produced a receptor binding-dependent reduction of fentanyl-induced respiratory depression. In chronic opioid users, a protective effect against high-dose fentanyl was observed at buprenorphine plasma concentrations &#8805;2&#160;ng/mL, suggesting that when buprenorphine MOR occupancy is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause further respiratory depression in addition to the mild respiratory effects of buprenorphine.</p></sec><sec id="sec0012"><label>5.3.3</label><title><underline>BRIXADI</underline>&#8482; <underline>(buprenorphine) extended-release injection for subcutaneous use</underline></title><p id="para0039">Another sustained-release subcutaneous buprenorphine formulation (weekly and monthly depots), CAM2038 (BRIXADI&#8482;), was developed using FluidCrystal&#174; Injection Depot Technology (Camurus AB, Lund, Sweden). Camurus and Braeburn Pharmaceuticals Inc. submitted the NDA for BRIXADI&#8482; weekly and monthly depots on July 19, 2017. PDUFA Priority Review designation was granted on September 18, 2017. A joint advisory committee of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee was held on November 1, 2017 to discuss the efficacy, safety, and benefit-risk profile of BRIXADI&#8482; weekly and monthly depots (<xref rid="bib0011" ref-type="bibr">Braeburn&#160;Pharmaceuticals,&#160;Inc., 2018</xref>). On December 21, 2018, Braeburn Pharmaceuticals, Inc., received FDA's tentative approval of BRIXADI&#8482;. However, Braeburn Pharmaceuticals, Inc., received a first complete response letter from the FDA in December 2020 and a second complete response letter in December 2021; BRIXADI&#8482; is not currently approved in the US. On December 8, 2022, Braeburn Pharmaceuticals, Inc. announced that resubmission of the NDA for BRIXADI&#8482; was accepted by the FDA with a PDUFA action date set for May 23, 2023 (<xref rid="bib0010" ref-type="bibr">Braeburn&#160;Inc., 2022</xref>). BRIXADI&#8482; is the US trademark for Camurus&#8217; product BUVIDAL&#174; (buprenorphine prolonged-release solution for subcutaneous injection in prefilled syringe) which was approved for the treatment of OUD in Europe and Australia.</p><p id="para0040">The FluidCrystal&#174; Injection Depot Technology (Camurus AB, Lund, Sweden) comprises a lipid-based liquid with a dissolved active ingredient. Once injected, the lipid solution transforms into a liquid crystalline gel that encapsulates buprenorphine and releases it as the depot biodegrades. BRIXADI&#8482; was developed in different fixed-dose compositions. The clinical development plan for BRIXADI&#8482; consisted of four PK studies of weekly and monthly BRIXADI in healthy volunteers or patients with OUD (<xref rid="bib0001" ref-type="bibr">Albayaty&#160;et&#160;al., 2017</xref>; <xref rid="bib0047" ref-type="bibr">Haasen&#160;et&#160;al., 2017</xref>), a phase II opioid-blockade study (<xref rid="bib0124" ref-type="bibr">Walsh&#160;et&#160;al., 2017</xref>), a 24-week, phase III, randomized, double-blind, double-dummy study of BRIXADI&#8482; versus daily sublingual buprenorphine/naloxone (<xref rid="bib0083" ref-type="bibr">Lofwall&#160;et&#160;al., 2018</xref>) and a 48-week, phase III, open-label, long-term safety study of BRIXADI&#8482; in new-to-treatment patients and patients switched from daily sublingual buprenorphine/naloxone (<xref rid="bib0032" ref-type="bibr">Frost&#160;et&#160;al., 2019</xref>).</p><p id="para0041">The phase II opioid-blockade study (<xref rid="bib0124" ref-type="bibr">Walsh&#160;et&#160;al., 2017</xref>) examined the efficacy of once-weekly BRIXADI&#8482; at two doses, 24&#160;mg and 32&#160;mg, to block the subjective drug-liking response to acute IM hydromorphone (6 and 18&#160;mg) and to suppress opioid withdrawal in a non&#8211;treatment-seeking OUD population. Both doses of weekly BRIXADI&#8482; suppressed responses to hydromorphone and opioid withdrawal over a 14-day period (two weekly injections).</p><p id="para0042">The phase III, double-blind, double-dummy study (<xref rid="bib0083" ref-type="bibr">Lofwall&#160;et&#160;al., 2018</xref>) randomized 428 adults with moderate-to-severe OUD to flexible dosing with weekly and monthly BRIXADI&#8482; or daily sublingual buprenorphine/naloxone. Primary endpoints were non-inferiority in the proportion of opioid-negative urine samples and responder rate. A responder was defined as having no evidence of illicit opioid use at nine pre-specified time points. Supplemental weekly 8&#160;mg subcutaneous injections of buprenorphine were allowed in both treatment groups. Non-inferiority between BRIXADI&#8482; and sublingual buprenorphine/naloxone was demonstrated for both primary endpoints. The safety profile of BRIXADI&#8482; was generally consistent with the known safety profile of buprenorphine with the exception of mild-to-moderate injection-site adverse events.</p><p id="para0043">The long-term safety of BRIXADI&#8482; weekly (8, 16, 24, or 32&#160;mg) and monthly (64, 96, 128, or 160&#160;mg) depots was assessed in a phase III, open-label, observational, multicenter, 48-week trial (<xref rid="bib0032" ref-type="bibr">Frost&#160;et&#160;al., 2019</xref>) in 227 adults (143 males and 84 females) with OUD who received BRIXADI&#8482;. Participants in this study were allowed to enter in two ways: 37 participants (16.3%) initiated treatment with BRIXADI&#8482; and 190 participants (83.7%) converted from sublingual buprenorphine. All participants receiving BRIXADI&#8482; were allowed dose adjustments as needed weekly at scheduled visits or with 8&#160;mg BRIXADI&#8482; supplemental injections at unscheduled visits up to a maximum weekly dose of 40&#160;mg per week. Participants receiving BRIXADI&#8482; monthly who needed additional temporary buprenorphine were allowed a maximum of two supplemental injections of 8&#160;mg BRIXADI&#8482; per week; dose adjustments could be made at investigator discretion at scheduled visits.</p></sec></sec></sec><sec id="sec0013"><label>6</label><title>Conclusions</title><p id="para0044">MOUD combined with psychosocial interventions is the most effective treatment option for patients suffering from OUD (<xref rid="bib0006" ref-type="bibr">ASAM,&#160;2020</xref>; <xref rid="bib0019" ref-type="bibr">Connock&#160;et&#160;al., 2007</xref>; <xref rid="bib0024" ref-type="bibr">Dugosh&#160;et&#160;al., 2016</xref>). MOUD has been shown to be associated with positive outcomes for reducing drug use, criminal activity (<xref rid="bib0037" ref-type="bibr">Gisev&#160;et&#160;al., 2019</xref>; <xref rid="bib0038" ref-type="bibr">Gossop&#160;et&#160;al., 2000</xref>; <xref rid="bib0095" ref-type="bibr">Oliver&#160;et&#160;al., 2010</xref>; <xref rid="bib0099" ref-type="bibr">R&#248;islien&#160;et&#160;al., 2014</xref>), risk behaviors and HIV-transmission (<xref rid="bib0084" ref-type="bibr">Marsch&#160;1998</xref>), overdoses, and overall mortality (<xref rid="bib0036" ref-type="bibr">Gisev&#160;et&#160;al., 2015</xref>; <xref rid="bib0106" ref-type="bibr">Sordo&#160;et&#160;al., 2017</xref>) as well as improving rates of retention in treatment (<xref rid="bib0074" ref-type="bibr">Lim&#160;et&#160;al., 2022</xref>).</p><p id="para0045">As a mu-opioid partial agonist, buprenorphine has a favorable pharmacological safety profile relative to full opioid receptor agonists (<xref rid="bib0125" ref-type="bibr">Walsh&#160;et&#160;al., 1994</xref>; <xref rid="bib0107" ref-type="bibr">Soyka&#160;2017</xref>), which may improve the therapeutic dosing margin for certain clinical subgroups including pregnant individuals (<xref rid="bib0012" ref-type="bibr">Brogly&#160;et&#160;al., 2014</xref>; <xref rid="bib0070" ref-type="bibr">Lee&#160;et&#160;al., 2019</xref>). Rapid induction helps patients to stabilize quickly and maximizes retention in treatment (<xref rid="bib0108" ref-type="bibr">Spreen&#160;et&#160;al., 2022</xref>; <xref rid="bib0128" ref-type="bibr">Wong&#160;et&#160;al., 2021</xref>). Although there are challenges to buprenorphine induction in the era of fentanyl, our understanding of the neuropharmacological mechanisms underlying this transition is advancing and can improve the benefit/risk ratio through appropriately selected lower- or higher-dose induction strategies (<xref rid="bib0043" ref-type="bibr">Greenwald&#160;et&#160;al., 2022</xref>).</p><p id="para0046">The increased availability of multiple FDA-approved formulations of buprenorphine over the past two decades, as described here, offers a promising treatment landscape that affords an unprecedented range of choices for healthcare providers and persons with OUD. Indeed, the proportion of persons with OUD receiving buprenorphine treatment monotonically increased during 2011&#8211;2020 from 2.7% to 16.2% (<xref rid="bib0111" ref-type="bibr">SAMHSA,&#160;2021b</xref>). It is hoped that these options will increase the likelihood that patients will enter and stay in treatment to accelerate their recovery. It is only through integrated clinical treatment programs that actively engage patients and their communities that we, as a society, will progressively break down barriers and misconceptions about substance use disorders and their treatment. Nonetheless, systemic barriers that have created &#8220;maximally disruptive care&#8221; for persons with OUD continue to pose challenges in reducing disparities in access to, and engagement in, treatment (<xref rid="bib0003" ref-type="bibr">Amiri&#160;et&#160;al., 2021</xref>; <xref rid="bib0026" ref-type="bibr">Englander&#160;et&#160;al., 2022</xref>); persistent efforts are needed to address this problem. Focusing on the importance of continuity of care across settings and underserved vulnerable populations with OUD, including adolescents (<xref rid="bib0013" ref-type="bibr">Camenga&#160;et&#160;al., 2019</xref>; <xref rid="bib0048" ref-type="bibr">Hadland et&#160;al., 2017</xref>), pregnant individuals (<xref rid="bib0082" ref-type="bibr">Link&#160;et&#160;al., 2020</xref>; <xref rid="bib0061" ref-type="bibr">Klaman&#160;et&#160;al., 2017</xref>), those involved in the criminal justice system (<xref rid="bib0027" ref-type="bibr">Evans&#160;et&#160;al., 2019</xref>), and economically disadvantaged persons, using lower-threshold approaches such as interim treatment (<xref rid="bib0102" ref-type="bibr">Sams&#243; et&#160;al., 2022</xref>) and telehealth (<xref rid="bib0046" ref-type="bibr">Guillen&#160;et&#160;al., 2022</xref>) will become increasingly critical. Furthermore, key aspects of OUD treatment must include monitoring patient progress in the short-, medium-, and long-term, focusing on retention in treatment (<xref rid="bib0019" ref-type="bibr">Connock&#160;et&#160;al., 2007</xref>; <xref rid="bib0060" ref-type="bibr">Kennedy&#160;et&#160;al., 2022</xref>; <xref rid="bib0062" ref-type="bibr">Klimas&#160;et&#160;al., 2021</xref>; <xref rid="bib0104" ref-type="bibr">Shulman&#160;et&#160;al., 2021</xref>), and providing evidence-based training to healthcare providers (<xref rid="bib0045" ref-type="bibr">Gugala&#160;et&#160;al., 2022</xref>). Incorporating harm reduction practices into MOUD (<xref rid="bib0040" ref-type="bibr">Greenwald,&#160;2018</xref>; <xref rid="bib0113" ref-type="bibr">Taylor&#160;et&#160;al., 2021</xref>), integrating care for persons with OUD and co-occurring mental health (<xref rid="bib0035" ref-type="bibr">Ghabrash&#160;et&#160;al., 2020</xref>) and medical problems (<xref rid="bib0029" ref-type="bibr">Fanucchi&#160;et&#160;al., 2019</xref>), and understanding better the underlying causes of return to opioid use are equally critical. The magnitude and dynamic nature of the opioid epidemic still requires significant investments to demonstrate that comprehensive drug treatment strategies lead to better outcomes that ultimately offset medical costs associated with substance use disorders and the associated costs of incarceration, shelter, and welfare when these burdensome conditions are untreated.</p></sec><sec id="sec0014"><title>Contributions</title><p id="para0047">CH contributed to the concept and design of this review, drafting of the manuscript and revising it critically for important intellectual content. PJF and MKG contributed to the drafting of the manuscript and revising it critically for important intellectual content. All authors approved the final version of the submitted manuscript.</p></sec><sec id="sec0015"><title>Disclosures</title><p id="para0048">CH and PJF are full-time employees of Indivior Inc. MKG has received consulting and speaker fees from Indivior Inc. unrelated to the preparation of this manuscript.</p></sec><sec sec-type="COI-statement" id="sec0016"><title>Declaration of Competing Interests</title><p id="para0049">CH and PJF are full-time employees of Indivior Inc. MKG has received consulting and speaker fees from Indivior Inc. unrelated to the preparation of this manuscript.</p><p id="para0050">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Albayaty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strandg&#229;rden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tiberg</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study</article-title><source>Adv. Ther.</source><volume>34</volume><issue>2</issue><year>2017</year><fpage>560</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1007/s12325-016-0472-9</pub-id><comment>PMID: 28070862</comment><pub-id pub-id-type="pmid">28070862</pub-id></element-citation></ref><ref id="bib0002"><element-citation publication-type="book" id="sbref0002"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><part-title>Diagnostic and Statistical Manual of Mental Disorders</part-title><edition>5th edition</edition><year>2013</year><publisher-name>American Psychiatric Association</publisher-name><publisher-loc>Arlington, Virginia</publisher-loc></element-citation></ref><ref id="bib0003"><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Amiri</surname><given-names>S.</given-names></name><name name-style="western"><surname>McDonell</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Denney</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Buchwald</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amram</surname><given-names>O.</given-names></name></person-group><article-title>Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis</article-title><source>Value Health</source><volume>24</volume><issue>2</issue><year>2021</year><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2020.08.2098</pub-id><pub-id pub-id-type="pmid">33518025</pub-id></element-citation></ref><ref id="bib0004"><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Andorn</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Haight</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Hassman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rutrick</surname><given-names>D.</given-names></name></person-group><article-title>Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis</article-title><source>J. Clin. Psychopharmacol.</source><volume>40</volume><issue>3</issue><year>2020</year><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000001195</pub-id><pub-id pub-id-type="pmid">32282418</pub-id><pub-id pub-id-type="pmcid">PMC7188268</pub-id></element-citation></ref><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Andraka-Christou</surname><given-names>B.</given-names></name></person-group><article-title>Addressing racial and ethnic disparities in the use of medications for opioid use disorder</article-title><source>Health Aff. (Millwood)</source><volume>40</volume><issue>6</issue><year>2021</year><fpage>920</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2020.02261</pub-id><pub-id pub-id-type="pmid">34097509</pub-id></element-citation></ref><ref id="bib0006"><mixed-citation publication-type="other" id="sbref0006">ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline" id="interref0001">https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline</ext-link>. doi:10.1097/ADM.0000000000000633.</mixed-citation></ref><ref id="bib0007"><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Bickel</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Stitzer</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Liebson</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Jasinski</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.E.</given-names></name></person-group><article-title>A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts</article-title><source>Clin. Pharmacol. Ther.</source><volume>43</volume><issue>1</issue><year>1988</year><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/clpt.1988.13</pub-id><pub-id pub-id-type="pmid">3275523</pub-id></element-citation></ref><ref id="bib0008"><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Bickel</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Stitzer</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Liebson</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Jasinski</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.E.</given-names></name></person-group><article-title>Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans</article-title><source>J. Pharmacol. Exp. Ther.</source><volume>247</volume><issue>1</issue><year>1988</year><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">2459370</pub-id></element-citation></ref><ref id="bib0009"><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Boyett</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Chilcoat</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name></person-group><article-title>Continued posttrial benefits of buprenorphine extended release: RECOVER study findings</article-title><source>J. Addict. Med.</source><year>2022</year><pub-id pub-id-type="doi">10.1097/ADM.0000000000001070</pub-id><comment>10.1097/ADM.0000000000001070PMID: 36111991</comment><pub-id pub-id-type="pmcid">PMC10022675</pub-id><pub-id pub-id-type="pmid">36111991</pub-id></element-citation></ref><ref id="bib0010"><mixed-citation publication-type="other" id="sbref0010">Braeburn Inc., 2022. FDA Accepts Braeburn's New Drug Application Resubmission For BRIXADI&#8482; (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder. Cision PR Newswire, Chicago. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html" id="interref0002">https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0011"><mixed-citation publication-type="other" id="sbref0011">Braeburn Pharmaceuticals, Inc., 2018. Braeburn announces FDA advisory committee recommends approval of CAM2038 buprenorphine depot for the treatment of opioid use disorder. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://braeburnrx.com/braeburn-announces-fda-advisory-committee-recommends-approval-of-cam2038-buprenorphine-depot-for-the-treatment-of-opioid-use-disorder/" id="interref0003">https://braeburnrx.com/braeburn-announces-fda-advisory-committee-recommends-approval-of-cam2038-buprenorphine-depot-for-the-treatment-of-opioid-use-disorder/</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0012"><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Brogly</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Saia</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Walley</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>P.</given-names></name></person-group><article-title>Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis</article-title><source>Am. J. Epidemiol.</source><volume>180</volume><issue>7</issue><year>2014</year><fpage>673</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1093/aje/kwu190</pub-id><pub-id pub-id-type="pmid">25150272</pub-id></element-citation></ref><ref id="bib0013"><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Camenga</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Colon-Rivera</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Muvvala</surname><given-names>S.B.</given-names></name></person-group><article-title>Medications for maintenance treatment of opioid use disorder in adolescents: a narrative review and assessment of clinical benefits and potential risks</article-title><source>J. Stud. Alcohol Drugs</source><volume>80</volume><issue>4</issue><year>2019</year><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">31495374</pub-id></element-citation></ref><ref id="bib0014"><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>A.M.</given-names></name></person-group><article-title>The history of the development of buprenorphine as an addiction therapeutic</article-title><source>Ann. N Y Acad. Sci.</source><volume>1248</volume><year>2012</year><fpage>124</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06352.x</pub-id><pub-id pub-id-type="pmid">22256949</pub-id></element-citation></ref><ref id="bib0015"><mixed-citation publication-type="other" id="sbref0015">Casetext, 2015. Psychopharmacologic Drugs Advisory Committee; Notice of Meeting. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://casetext.com/federal-register/psychopharmacologic-drugs-advisory-committee-notice-of-meeting-16" id="interref0004">https://casetext.com/federal-register/psychopharmacologic-drugs-advisory-committee-notice-of-meeting-16</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0016"><mixed-citation publication-type="other" id="sbref0016">Centers for Disease Control and Prevention (CDC), 2022. Vital Statistics Rapid Release: Provisional Drug Overdose Data. Centers for Disease Control and Prevention. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" id="interref0005">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0017"><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badolato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Segoshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vasudevan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Badiei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sugarman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mangat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giftos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Tofighi</surname><given-names>B.</given-names></name></person-group><article-title>Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study</article-title><source>Addict. Sci. Clin. Pract.</source><volume>17</volume><issue>1</issue><year>2022</year><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13722-022-00288-4</pub-id><pub-id pub-id-type="pmid">35093164</pub-id><pub-id pub-id-type="pmcid">PMC8800291</pub-id></element-citation></ref><ref id="bib0018"><mixed-citation publication-type="other" id="sbref0018">Comprehensive Addiction and Recovery Act (CARA), Pub. L. No 114&#8211;198, 2016, July 22.</mixed-citation></ref><ref id="bib0019"><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Connock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Juarez-Garcia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jowett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frew</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>RJ.</given-names></name><name name-style="western"><surname>Fry-Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Day</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Burls</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.S.</given-names></name></person-group><article-title>Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation</article-title><source>Health Technol. Assess.</source><volume>11</volume><issue>9</issue><year>2007</year><fpage>1</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.3310/hta11090</pub-id><comment>iii-iv</comment><pub-id pub-id-type="pmid">17313907</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Cotton</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kurtz</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Waldbauer</surname><given-names>L.</given-names></name></person-group><article-title>Extended-release buprenorphine outcomes among treatment resistant veterans</article-title><source>Am. J. Drug Alcohol Abuse</source><volume>48</volume><issue>3</issue><year>2022</year><fpage>334</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1080/00952990.2021.1992773</pub-id><pub-id pub-id-type="pmid">34780319</pub-id></element-citation></ref><ref id="bib0021"><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Craft</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Tegge</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Athamneh</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Chilcoat</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Le Moigne</surname><given-names>A.</given-names></name><name name-style="western"><surname>DeVeaugh-Geiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>W.K.</given-names></name></person-group><article-title>Recovery from opioid use disorder: a 4-year post-clinical trial outcomes study</article-title><source>Drug Alcohol Depend.</source><volume>234</volume><year>2022</year><object-id pub-id-type="publisher-id">109389</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109389</pub-id><pub-id pub-id-type="pmid">35287034</pub-id></element-citation></ref><ref id="bib0022"><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Dole</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Nyswander</surname><given-names>M.</given-names></name></person-group><article-title>A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride</article-title><source>JAMA</source><volume>23</volume><issue>193</issue><year>1965</year><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1001/jama.1965.03090080008002</pub-id><comment>1965</comment><pub-id pub-id-type="pmid">14321530</pub-id></element-citation></ref><ref id="bib0023"><mixed-citation publication-type="other" id="sbref0023">Drug Addiction Treatment Act of 2000 (DATA 2000), 2000, October 17. Pub. L. No. 106&#8211;310.</mixed-citation></ref><ref id="bib0024"><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Dugosh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>B.</given-names></name><name name-style="western"><surname>McLoyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chalk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Festinger</surname><given-names>D.</given-names></name></person-group><article-title>A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction</article-title><source>J. Addict. Med.</source><volume>10</volume><issue>2</issue><year>2016</year><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000193</pub-id><pub-id pub-id-type="pmid">26808307</pub-id><pub-id pub-id-type="pmcid">PMC4795974</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deseran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>I.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>B.D.</given-names></name></person-group><article-title>Monthly patient volumes of buprenorphine-waivered clinicians in the US</article-title><source>JAMA Network Open</source><volume>3</volume><issue>8</issue><year>2020</year><pub-id pub-id-type="doi">10.1001/JAMANETWORKOPEN.2020.14045</pub-id><comment>e2014045&#8211;e2014045</comment><pub-id pub-id-type="pmcid">PMC7445589</pub-id><pub-id pub-id-type="pmid">32833015</pub-id></element-citation></ref><ref id="bib0026"><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Englander</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Levander</surname><given-names>X.A.</given-names></name></person-group><article-title>Envisioning minimally disruptive opioid use disorder care</article-title><source>J. Gen. Intern. Med.</source><year>2022</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s11606-022-07939-x</pub-id><pub-id pub-id-type="pmcid">PMC9676870</pub-id><pub-id pub-id-type="pmid">36401107</pub-id></element-citation></ref><ref id="bib0027"><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hser</surname><given-names>Y.I.</given-names></name></person-group><article-title>Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder</article-title><source>Addiction</source><volume>114</volume><issue>8</issue><year>2019</year><fpage>1396</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1111/add.14620</pub-id><pub-id pub-id-type="pmid">30916463</pub-id><pub-id pub-id-type="pmcid">PMC6626574</pub-id></element-citation></ref><ref id="bib0028"><mixed-citation publication-type="other" id="sbref0028">emc, 2020, November 24. Temgesic Injection 1&#160;ml, Summary of Product Characteristics. Indivior UK Limited, Slough, UK. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/1141/smpc#gref" id="interref0006">https://www.medicines.org.uk/emc/product/1141/smpc#gref</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0029"><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Fanucchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Korthuis</surname><given-names>P.T.</given-names></name></person-group><article-title>Medications for treatment of opioid use disorder among persons living with HIV</article-title><source>Curr HIV/AIDS Rep</source><volume>16</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s11904-019-00436-7</pub-id><pub-id pub-id-type="pmid">30684117</pub-id><pub-id pub-id-type="pmcid">PMC6420833</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grebely</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Larance</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dore</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montebello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name><collab>CoLAB study team</collab></person-group><article-title>Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence</article-title><source>Int. J. Drug Policy</source><volume>100</volume><year>2022</year><object-id pub-id-type="publisher-id">103492</object-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103492</pub-id><pub-id pub-id-type="pmid">34736130</pub-id></element-citation></ref><ref id="bib0031"><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Feroni</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>A.</given-names></name></person-group><article-title>Public regulation measures for a sensitive drug: the case of Subutex&#174;, opiate replacement therapy</article-title><source>French J. Social Affairs (Revue fran&#231;aise des affaires sociales)</source><volume>3&#8211;4</volume><year>2007</year><fpage>153</fpage><lpage>170</lpage><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cairn-int.info/journal-2007-3-page-153.htm" id="interref0007">https://www.cairn-int.info/journal&#8211;2007-3-page-153.htm</ext-link><comment>Accessed December 14, 2022</comment></element-citation></ref><ref id="bib0032"><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Strang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Haber</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oosman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tiberg</surname><given-names>F.</given-names></name></person-group><article-title>Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder</article-title><source>Addiction</source><volume>114</volume><issue>8</issue><year>2019</year><fpage>1416</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1111/add.14636</pub-id><pub-id pub-id-type="pmid">31013390</pub-id><pub-id pub-id-type="pmcid">PMC6771955</pub-id></element-citation></ref><ref id="bib0033"><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bridge</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williford</surname><given-names>W.O.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raisch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casadonte</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Malkerneker</surname><given-names>U.</given-names></name><name name-style="western"><surname>McNicholas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Renner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tusel</surname><given-names>D.</given-names></name><collab>Buprenorphine/Naloxone Collaborative Study Group</collab></person-group><article-title>Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone</article-title><source>N. Engl. J. Med.</source><volume>349</volume><issue>10</issue><year>2003</year><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa022164</pub-id><pub-id pub-id-type="pmid">12954743</pub-id></element-citation></ref><ref id="bib0034"><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Macfadden</surname><given-names>W.</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.N.</given-names></name></person-group><article-title>Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts</article-title><source>Drug Alcohol Depend.</source><volume>50</volume><issue>1</issue><year>1998</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/s0376-8716(98)00008-8</pub-id><pub-id pub-id-type="pmid">9589267</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Ghabrash</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Bahremand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veilleux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blais-Normandin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chicoine</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sutra-Cole</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dubreucq</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juteau</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Lestage</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jutras-Aswad</surname><given-names>D.</given-names></name></person-group><article-title>Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review</article-title><source>J. Dual Diagn.</source><volume>16</volume><issue>2</issue><year>2020</year><fpage>191</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1080/15504263.2020.1726549</pub-id><pub-id pub-id-type="pmid">32089124</pub-id></element-citation></ref><ref id="bib0036"><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Gisev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weatherburn</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mattick</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Larney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>L.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name></person-group><article-title>A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence</article-title><source>Addiction</source><volume>110</volume><issue>12</issue><year>2015</year><fpage>1975</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1111/add.13073</pub-id><pub-id pub-id-type="pmid">26212260</pub-id></element-citation></ref><ref id="bib0037"><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Gisev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bharat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weatherburn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name></person-group><article-title>The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study</article-title><source>Lancet Public Health</source><volume>4</volume><issue>7</issue><year>2019</year><fpage>e334</fpage><lpage>e342</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(19)30060-X</pub-id><pub-id pub-id-type="pmid">31201133</pub-id><pub-id pub-id-type="pmcid">PMC6673674</pub-id></element-citation></ref><ref id="bib0038"><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Gossop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rolfe</surname><given-names>A.</given-names></name></person-group><article-title>Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study</article-title><source>Drug Alcohol Depend.</source><volume>60</volume><issue>3</issue><year>2000</year><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/s0376-8716(00)00109-5</pub-id><pub-id pub-id-type="pmid">11053762</pub-id></element-citation></ref><ref id="bib0039"><element-citation publication-type="book" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name></person-group><part-title>Human experimental therapeutic models in opioid dependence: translational research advances and implications</part-title><person-group person-group-type="editor"><name name-style="western"><surname>McKenna</surname><given-names>C.R.</given-names></name></person-group><source>Trends in Substance Abuse Research</source><year>2006</year><publisher-name>Nova Science Publishers, Inc.</publisher-name><publisher-loc>New York</publisher-loc><fpage>1</fpage><lpage>55</lpage></element-citation></ref><ref id="bib0040"><element-citation publication-type="book" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name></person-group><part-title>Opioid substitution treatment and harm minimization approaches</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Pickard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.H.</given-names></name></person-group><source>The Routledge Handbook of Philosophy and Science of Addiction</source><year>2018</year><publisher-name>Routledge Press</publisher-name><publisher-loc>New York</publisher-loc><fpage>478</fpage><lpage>489</lpage></element-citation></ref><ref id="bib0041"><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Johanson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Moody</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kilbourn</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Zubieta</surname><given-names>J.K.</given-names></name></person-group><article-title>Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers</article-title><source>Neuropsychopharmacology</source><volume>28</volume><issue>11</issue><year>2003</year><fpage>2000</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300251</pub-id><pub-id pub-id-type="pmid">12902992</pub-id></element-citation></ref><ref id="bib0042"><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Johanson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Bueller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moody</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Kilbourn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zubieta</surname><given-names>J.K.</given-names></name></person-group><article-title>Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices</article-title><source>Biol. Psychiatry</source><volume>61</volume><issue>1</issue><year>2007</year><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2006.04.043</pub-id><pub-id pub-id-type="pmid">16950210</pub-id></element-citation></ref><ref id="bib0043"><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Herring</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>P.</given-names></name></person-group><article-title>A neuropharmacological model to explain buprenorphine induction challenges</article-title><source>Ann. Emerg. Med.</source><volume>80</volume><issue>6</issue><year>2022</year><fpage>509</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2022.05.032</pub-id><pub-id pub-id-type="pmid">35940992</pub-id></element-citation></ref><ref id="bib0044"><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Gryczynski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Salkever</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>J.H.</given-names></name></person-group><article-title>Patterns in admission delays to outpatient methadone treatment in the United States</article-title><source>J. Subst. Abuse Treat.</source><volume>41</volume><issue>4</issue><year>2011</year><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2011.06.005</pub-id><pub-id pub-id-type="pmid">21821378</pub-id><pub-id pub-id-type="pmcid">PMC3205308</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Gugala</surname><given-names>E.</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>O.</given-names></name><name name-style="western"><surname>Moczygemba</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>L.G.</given-names></name></person-group><article-title>Opioid harm reduction: a scoping review of physician and system-level gaps in knowledge, education, and practice</article-title><source>Subst. Abus.</source><volume>43</volume><issue>1</issue><year>2022</year><fpage>972</fpage><lpage>987</lpage><comment>doi:0.1080/08897077.2022.2060423</comment><pub-id pub-id-type="pmid">35426772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2022.2060423</pub-id></element-citation></ref><ref id="bib0046"><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Guillen</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saadat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>B.</given-names></name></person-group><article-title>Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review</article-title><source>Telemed. J. E Health</source><volume>28</volume><issue>6</issue><year>2022</year><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1089/tmj.2021.0308</pub-id><comment>Epub 2021 Oct 29. PMID: 34714172</comment><pub-id pub-id-type="pmid">34714172</pub-id></element-citation></ref><ref id="bib0047"><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Haasen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiberg</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder</article-title><source>J. Subst. Abuse Treat.</source><volume>78</volume><year>2017</year><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2017.04.008</pub-id><comment>PMID: 28554599</comment><pub-id pub-id-type="pmid">28554599</pub-id></element-citation></ref><ref id="bib0048"><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Hadland</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Wharam</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Samet</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>M.R.</given-names></name></person-group><article-title>Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014</article-title><source>JAMA Pediatr.</source><volume>171</volume><issue>8</issue><year>2017</year><fpage>747</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2017.0745</pub-id><pub-id pub-id-type="pmid">28628701</pub-id><pub-id pub-id-type="pmcid">PMC5649381</pub-id></element-citation></ref><ref id="bib0049"><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Haffajee</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A.S.B.B.</given-names></name><name name-style="western"><surname>Goldstick</surname><given-names>J.E.</given-names></name></person-group><article-title>Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder</article-title><source>JAMA Network Open</source><volume>2</volume><issue>6</issue><year>2019</year><object-id pub-id-type="publisher-id">e196373</object-id><pub-id pub-id-type="doi">10.1001/ja-manetworkopen.2019.6373</pub-id><pub-id pub-id-type="pmcid">PMC6604101</pub-id><pub-id pub-id-type="pmid">31251376</pub-id></element-citation></ref><ref id="bib0050"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wanderling</surname><given-names>J.</given-names></name><name name-style="western"><surname>DiRocco</surname><given-names>D.</given-names></name></person-group><article-title>Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City</article-title><source>Drug Alcohol Depend.</source><volume>164</volume><year>2016</year><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.03.028</pub-id><pub-id pub-id-type="pmid">27179822</pub-id><pub-id pub-id-type="pmcid">PMC5539992</pub-id></element-citation></ref><ref id="bib0051"><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Haight</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Garofalo</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name><collab>RB-US-13-0001 Study Investigators</collab></person-group><article-title>Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><volume>393</volume><issue>10173</issue><year>2019</year><fpage>778</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32259-1</pub-id><pub-id pub-id-type="pmid">30792007</pub-id></element-citation></ref><ref id="bib0052"><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Holland</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vivolo-Kantor</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Idaikkadar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zwald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoots</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yard</surname><given-names>E.</given-names></name><name name-style="western"><surname>D'Inverno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swedo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Petrosky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Board</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Law</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coletta</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Adjemian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puddy</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>G.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Houry</surname><given-names>D.</given-names></name></person-group><article-title>Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 Pandemic</article-title><source>JAMA Psychiatry</source><volume>78</volume><issue>4</issue><year>2021</year><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.4402</pub-id><pub-id pub-id-type="pmid">33533876</pub-id><pub-id pub-id-type="pmcid">PMC7859873</pub-id></element-citation></ref><ref id="bib0053"><mixed-citation publication-type="other" id="sbref0053">Indivior Inc., 2022, June. SUBLOCADE&#8482; Full Prescribing Information. North Chesterfield, VA. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209819s010lbl.pdf" id="interref0008">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209819s010lbl.pdf</ext-link></mixed-citation></ref><ref id="bib0054"><element-citation publication-type="book" id="sbref0054"><comment>R. A.</comment><person-group person-group-type="author"><collab>Institute of Medicine</collab></person-group><part-title>Committee on federal regulations of methadone treatment, division of biobehavioral sciences and mental disorders in rettig</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Yarmolinsky</surname><given-names>A.</given-names></name></person-group><source>Federal Regulation of Methadone Treatment</source><year>1995</year><publisher-name>National Academy Press</publisher-name><publisher-loc>Washington, D.C</publisher-loc><fpage>96</fpage><comment>129</comment></element-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>O'Keeffe</surname><given-names>C.</given-names></name></person-group><article-title>From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States</article-title><source>Drug Alcohol Depend.</source><volume>70</volume><issue>2 Suppl</issue><year>2003</year><fpage>S3</fpage><lpage>S11</lpage><pub-id pub-id-type="other">10.1016/s0376-8716(03)00055 3</pub-id><pub-id pub-id-type="pmid">12738346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0376-8716(03)00055-3</pub-id></element-citation></ref><ref id="bib0056"><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Jasinski</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Pevnick</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>J.D.</given-names></name></person-group><article-title>Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction</article-title><source>Arch. Gen. Psychiatry</source><volume>35</volume><issue>4</issue><year>1978</year><fpage>501</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1978.01770280111012</pub-id><pub-id pub-id-type="pmid">215096</pub-id></element-citation></ref><ref id="bib0057"><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name></person-group><article-title>A controlled trial of buprenorphine treatment for opioid dependence</article-title><source>JAMA</source><volume>267</volume><issue>20</issue><year>1992</year><fpage>2750</fpage><lpage>2755</lpage><pub-id pub-id-type="pmid">1578593</pub-id></element-citation></ref><ref id="bib0058"><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bekheet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G.C.</given-names></name></person-group><article-title>The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms</article-title><source>Epidemiol. Rev.</source><volume>42</volume><issue>1</issue><year>2020</year><fpage>154</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxaa011</pub-id><pub-id pub-id-type="pmid">33511987</pub-id><pub-id pub-id-type="pmcid">PMC9200066</pub-id></element-citation></ref><ref id="bib0059"><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Vythilingam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schier</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Eisenstat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Compton</surname><given-names>W.M.</given-names></name></person-group><article-title>Characteristics and correlates of US clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic</article-title><source>Drug Alcohol Depend.</source><volume>225</volume><year>2021</year><object-id pub-id-type="publisher-id">108783</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108783</pub-id><pub-id pub-id-type="pmcid">PMC9186054</pub-id><pub-id pub-id-type="pmid">34049102</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wessel</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>R.</given-names></name><name name-style="western"><surname>Downer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osakue</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Merlin</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Liebschutz</surname><given-names>J.M.</given-names></name></person-group><article-title>Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review</article-title><source>J. Gen. Intern. Med.</source><volume>37</volume><issue>2</issue><year>2022</year><fpage>332</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-06448-z</pub-id><pub-id pub-id-type="pmid">33469778</pub-id><pub-id pub-id-type="pmcid">PMC8810983</pub-id></element-citation></ref><ref id="bib0061"><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Klaman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leopold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perpich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vender</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campopiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name></person-group><article-title>Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance</article-title><source>J Addict Med</source><volume>11</volume><issue>3</issue><year>2017</year><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000308</pub-id><pub-id pub-id-type="pmid">28406856</pub-id><pub-id pub-id-type="pmcid">PMC5457836</pub-id></element-citation></ref><ref id="bib0062"><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Klimas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gorfinkel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E.</given-names></name></person-group><article-title>Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials</article-title><source>Syst. Rev.</source><volume>10</volume><issue>1</issue><year>2021</year><fpage>216</fpage><pub-id pub-id-type="doi">10.1186/s13643-021-01764-9</pub-id><pub-id pub-id-type="pmid">34362464</pub-id><pub-id pub-id-type="pmcid">PMC8348786</pub-id></element-citation></ref><ref id="bib0064"><mixed-citation publication-type="other" id="sbref0064">Kolberg R., 1995. Bridges to Baltimore: NIDA's Addiction Research Center. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://nihsearch.cit.nih.gov/catalyst/back/95.05/a.nida.html" id="interref0009">https://nihsearch.cit.nih.gov/catalyst/back/95.05/a.nida.html</ext-link>. (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jent</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hadland</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M.</given-names></name></person-group><article-title>Utilization of medications for opioid use disorder across US states: relationship to treatment availability and overdose mortality</article-title><source>J. Addict. Med.</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1097/adm.0000000000000820</pub-id><pub-id pub-id-type="pmid">35120067</pub-id></element-citation></ref><ref id="bib0066"><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Jent</surname><given-names>V.</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M.</given-names></name></person-group><article-title>Has the treatment gap for opioid use disorder narrowed in the US?: a yearly assessment from 2010 to 2019</article-title><source>Int. J. Drug Policy</source><year>2022</year><object-id pub-id-type="publisher-id">103786</object-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2022.103786</pub-id><comment>PMID: 35934583</comment><pub-id pub-id-type="pmcid">PMC10976290</pub-id><pub-id pub-id-type="pmid">35934583</pub-id></element-citation></ref><ref id="bib0067"><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Gomeni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.P.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Nasser</surname><given-names>A.F.</given-names></name></person-group><article-title>Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder</article-title><source>J. Clin. Pharmacol.</source><volume>56</volume><issue>7</issue><year>2016</year><fpage>806</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1002/jcph.665</pub-id><pub-id pub-id-type="pmid">26479717</pub-id></element-citation></ref><ref id="bib0068"><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ngaimisi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ivaturi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Young</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder</article-title><source>Front. Pharmacol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">1052113</object-id><pub-id pub-id-type="doi">10.3389/fphar.2022.1052113</pub-id><pub-id pub-id-type="pmcid">PMC9715596</pub-id><pub-id pub-id-type="pmid">36467036</pub-id></element-citation></ref><ref id="bib0069"><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>Langabeer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Gourishankar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Champagne-Langabeer</surname><given-names>T.</given-names></name></person-group><article-title>Disparities between US opioid overdose deaths and treatment capacity: a geospatial and descriptive analysis</article-title><source>J. Addict. Med.</source><volume>13</volume><issue>6</issue><year>2019</year><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000523</pub-id><pub-id pub-id-type="pmid">30844879</pub-id></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>M.</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Loukas Ryan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.A.</given-names></name></person-group><article-title>Brief report: low-barrier buprenorphine initiation predicts treatment retention among Latinx and non-Latinx primary care patients</article-title><source>Am. J. Addict.</source><volume>28</volume><issue>5</issue><year>2019</year><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/ajad.12925</pub-id><pub-id pub-id-type="pmid">31251426</pub-id><pub-id pub-id-type="pmcid">PMC6706284</pub-id></element-citation></ref><ref id="bib0071"><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>M.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vasudevan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tofighi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garment</surname><given-names>A.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goldfeld</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Matteo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mangat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Katyal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giftos</surname><given-names>J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>R.</given-names></name></person-group><article-title>Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail</article-title><source>JAMA Netw. Open</source><volume>4</volume><issue>9</issue><year>2021</year><object-id pub-id-type="publisher-id">e2123032</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.23032</pub-id><pub-id pub-id-type="pmcid">PMC8427378</pub-id><pub-id pub-id-type="pmid">34495340</pub-id></element-citation></ref><ref id="bib0072"><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>J.W.</given-names></name></person-group><article-title>Buprenorphine</article-title><source>Drug Alcohol Depend.</source><volume>14</volume><issue>3&#8211;4</issue><year>1985</year><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/03768716(85)900675</pub-id><pub-id pub-id-type="pmid">2986930</pub-id></element-citation></ref><ref id="bib0073"><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>J.W.</given-names></name></person-group><article-title>In pursuit of the Holy Grail. Nathan B Eddy Award Address</article-title><source>NIDA Res. Monogr.</source><volume>179</volume><year>1999</year><fpage>7</fpage><lpage>13</lpage></element-citation></ref><ref id="bib0074"><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farhat</surname><given-names>I.</given-names></name><name name-style="western"><surname>Douro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panagiotoglou</surname><given-names>D</given-names></name></person-group><article-title>Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials</article-title><source>PLoS ONE</source><volume>17</volume><issue>3</issue><year>2022</year><object-id pub-id-type="publisher-id">e0266142</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0266142</pub-id><pub-id pub-id-type="pmcid">PMC8970369</pub-id><pub-id pub-id-type="pmid">35358261</pub-id></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Casadonte</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kampman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Patkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Beebe</surname><given-names>K.L.</given-names></name></person-group><article-title>Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial</article-title><source>JAMA</source><volume>304</volume><issue>14</issue><year>2010</year><fpage>1576</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1427</pub-id><pub-id pub-id-type="pmid">20940383</pub-id></element-citation></ref><ref id="bib0076"><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Charuvastra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Batki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.S.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kintaudi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wesson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>McNicholas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tusel</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Malkerneker</surname><given-names>U.</given-names></name><name name-style="western"><surname>Renner</surname><given-names>J.A.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Santos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Casadonte</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>D.</given-names></name></person-group><article-title>Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial</article-title><source>Addiction</source><volume>93</volume><issue>4</issue><year>1998</year><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1046/j.1360-0443.1998.9344753.x</pub-id><comment>Accessed December 14, 2022</comment><pub-id pub-id-type="pmid">9684386</pub-id></element-citation></ref><ref id="bib0077"><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study</article-title><source>J. Addict. Med.</source><volume>13</volume><issue>6</issue><year>2019</year><fpage>442</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000517</pub-id><pub-id pub-id-type="pmid">30844878</pub-id><pub-id pub-id-type="pmcid">PMC6844648</pub-id></element-citation></ref><ref id="bib0078"><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Farabee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Perrochet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the treatment effectiveness assessment</article-title><source>Subst. Abuse Rehabil.</source><volume>10</volume><year>2019</year><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2147/SAR.S198361</pub-id><pub-id pub-id-type="pmid">31239805</pub-id><pub-id pub-id-type="pmcid">PMC6556477</pub-id></element-citation></ref><ref id="bib0079"><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Albright</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Aldridge</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics</article-title><source>Contemp. Clin. Trials</source><volume>76</volume><year>2019</year><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.cct.2018.11.015</pub-id><pub-id pub-id-type="pmid">30508592</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study</article-title><source>J. Subst. Abuse Treat.</source><volume>110</volume><year>2020</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.11.004</pub-id><pub-id pub-id-type="pmid">31952623</pub-id></element-citation></ref><ref id="bib0081"><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Aldridge</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Solem</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Chilcoat</surname><given-names>H.</given-names></name><name name-style="western"><surname>Albright</surname><given-names>V.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Learned</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study</article-title><source>J. Addict. Med.</source><volume>14</volume><issue>5</issue><year>2020</year><fpage>e233</fpage><lpage>e240</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000647</pub-id><comment>PMID: 32187112; PMCID: PMC7547872</comment><pub-id pub-id-type="pmid">32187112</pub-id><pub-id pub-id-type="pmcid">PMC7547872</pub-id></element-citation></ref><ref id="bib0082"><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name name-style="western"><surname>Link</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaltenbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seligman</surname><given-names>N.</given-names></name></person-group><article-title>Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis</article-title><source>Am. J. Obstet. Gynecol. MFM</source><volume>2</volume><issue>3</issue><year>2020</year><object-id pub-id-type="publisher-id">100179</object-id><pub-id pub-id-type="doi">10.1016/j.ajogmf.2020.100179</pub-id><pub-id pub-id-type="pmid">33345863</pub-id></element-citation></ref><ref id="bib0083"><element-citation publication-type="journal" id="sbref0083"><person-group person-group-type="author"><name name-style="western"><surname>Lofwall</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Sigmon</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kampman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oosman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial</article-title><source>JAMA Intern. Med.</source><volume>178</volume><issue>6</issue><year>2018</year><fpage>764</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.1052</pub-id><pub-id pub-id-type="pmid">29799968</pub-id><pub-id pub-id-type="pmcid">PMC6145749</pub-id></element-citation></ref><ref id="bib0084"><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name name-style="western"><surname>Marsch</surname><given-names>L.A.</given-names></name></person-group><article-title>The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis</article-title><source>Addiction</source><volume>93</volume><issue>4</issue><year>1998</year><fpage>515</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1046/j.1360-0443.1998.9345157.x</pub-id><pub-id pub-id-type="pmid">9684390</pub-id></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Mendelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Upton</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Everhart</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Jones</surname><given-names>R.T.</given-names></name></person-group><article-title>Bioavailability of sublingual buprenorphine</article-title><source>J. Clin. Pharmacol.</source><volume>37</volume><issue>1</issue><year>1997</year><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1177/009127009703700106</pub-id><pub-id pub-id-type="pmid">9048270</pub-id></element-citation></ref><ref id="bib0086"><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name name-style="western"><surname>Mendelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Welm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Batki</surname><given-names>S.L.</given-names></name></person-group><article-title>Buprenorphine and naloxone interactions in methadone maintenance patients</article-title><source>Biol. Psychiatry</source><volume>41</volume><issue>11</issue><year>1997</year><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(96)00266-1</pub-id><pub-id pub-id-type="pmid">9146820</pub-id></element-citation></ref><ref id="bib0087"><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name name-style="western"><surname>Mendelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Welm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baggott</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Melby</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>R.P.</given-names></name></person-group><article-title>Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers</article-title><source>Psychopharmacology</source><volume>141</volume><issue>1</issue><year>1999</year><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/s002130050804</pub-id><pub-id pub-id-type="pmid">9952063</pub-id></element-citation></ref><ref id="bib0088"><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Algera</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Strafford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Velzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heuberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niesters</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olofsen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>G.J.</given-names></name></person-group><article-title>Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients</article-title><source>PLoS ONE</source><volume>17</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">e0256752</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0256752</pub-id><comment>PMID: 35085249; PMCID: PMC8794186</comment><pub-id pub-id-type="pmcid">PMC8794186</pub-id><pub-id pub-id-type="pmid">35085249</pub-id></element-citation></ref><ref id="bib0089"><mixed-citation publication-type="other" id="sbref0089">Narcotic Addict Treatment Act of 1974 (NATA), Pub. L. No. 93-281, p. 29, 1974, May 14. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/93rd-congress/senate-bill/1115/text" id="interref0010">https://www.congress.gov/bill/93rd-congress/senate-bill/1115/text</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Nasser</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Greenwald</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Vince</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fudala</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Twumasi-Ankrah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.P.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Heidbreder</surname><given-names>C.</given-names></name></person-group><article-title>Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder</article-title><source>J. Clin. Psychopharmacol.</source><volume>36</volume><issue>1</issue><year>2016</year><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000434</pub-id><pub-id pub-id-type="pmid">26650971</pub-id><pub-id pub-id-type="pmcid">PMC5549150</pub-id></element-citation></ref><ref id="bib0092"><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name name-style="western"><surname>Nath</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Upton</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Everhart</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shwonek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Mendelson</surname><given-names>J.E.</given-names></name></person-group><article-title>Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations</article-title><source>J. Clin. Pharmacol.</source><volume>39</volume><issue>6</issue><year>1999</year><fpage>619</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1177/00912709922008236</pub-id><pub-id pub-id-type="pmid">10354966</pub-id></element-citation></ref><ref id="bib0093"><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name name-style="western"><surname>Niles</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Gudin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Radcliff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>H.W.</given-names></name></person-group><article-title>The opioid epidemic within the COVID-19 pandemic: drug testing in 2020</article-title><source>Popul. Health Manage.</source><volume>24</volume><issue>S1</issue><year>2021</year><fpage>S43</fpage><lpage>S51</lpage><pub-id pub-id-type="doi">10.1089/pop.2020.0230</pub-id><pub-id pub-id-type="pmcid">PMC7875135</pub-id><pub-id pub-id-type="pmid">33031013</pub-id></element-citation></ref><ref id="bib0094"><mixed-citation publication-type="other" id="sbref0094">Office of National Drug Control Policy (ONDCP) Reauthorization Act of 2006, Pub. L. No. 109-469, 2006. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/109/plaws/publ469/PLAW-109publ469.pdf" id="interref0011">https://www.congress.gov/109/plaws/publ469/PLAW-109publ469.pdf</ext-link> (Accessed December 14, 2022)</mixed-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>P.</given-names></name><name name-style="western"><surname>Keen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowse</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ewins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mathers</surname><given-names>N.</given-names></name></person-group><article-title>The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service</article-title><source>Addiction</source><volume>105</volume><issue>4</issue><year>2010</year><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2009.02856.x</pub-id><pub-id pub-id-type="pmid">20403022</pub-id></element-citation></ref><ref id="bib0096"><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name name-style="western"><surname>Olofsen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Algera</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>van Velzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niesters</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name></person-group><article-title>Modeling buprenorphine reduction of fentanyl-induced respiratory depression</article-title><source>JCI Insight</source><volume>7</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">e156973</object-id><pub-id pub-id-type="doi">10.1172/jci.insight.156973</pub-id><comment>PMID: 35316224; PMCID: PMC909024</comment><pub-id pub-id-type="pmcid">PMC9090248</pub-id><pub-id pub-id-type="pmid">35316224</pub-id></element-citation></ref><ref id="bib0097"><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name name-style="western"><surname>Pro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zaller</surname><given-names>N.</given-names></name></person-group><article-title>Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in US healthcare settings</article-title><source>PLoS ONE</source><volume>15</volume><issue>2</issue><year>2020</year><object-id pub-id-type="publisher-id">e0228755</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0228755</pub-id><pub-id pub-id-type="pmcid">PMC7004348</pub-id><pub-id pub-id-type="pmid">32027723</pub-id></element-citation></ref><ref id="bib0098"><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name name-style="western"><surname>Rodda</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>West</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>LeSaint</surname><given-names>K.T.</given-names></name></person-group><article-title>Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic</article-title><source>J. Urban Health</source><volume>97</volume><issue>6</issue><year>2020</year><fpage>808</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1007/s11524-020-00486-y</pub-id><pub-id pub-id-type="pmid">32989667</pub-id><pub-id pub-id-type="pmcid">PMC7521564</pub-id></element-citation></ref><ref id="bib0099"><element-citation publication-type="journal" id="sbref0099"><person-group person-group-type="author"><name name-style="western"><surname>R&#248;islien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gran</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bukten</surname><given-names>A.</given-names></name></person-group><article-title>Accounting for individual differences and timing of events: estimating the effect of treatment on criminal convictions in heroin users</article-title><source>BMC Med. Res. Methodol.</source><volume>14</volume><year>2014</year><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-14-68</pub-id><pub-id pub-id-type="pmid">24886472</pub-id><pub-id pub-id-type="pmcid">PMC4040473</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Ronquest</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Willson</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Montejano</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Nadipelli</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Wollschlaeger</surname><given-names>B.A.</given-names></name></person-group><article-title>Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder</article-title><source>Subst. Abuse Rehabil.</source><volume>9</volume><year>2018</year><fpage>59</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.2147/SAR.S150253</pub-id><pub-id pub-id-type="pmid">30310349</pub-id><pub-id pub-id-type="pmcid">PMC6165853</pub-id></element-citation></ref><ref id="bib0101"><element-citation publication-type="journal" id="sbref0101"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Lofwall</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beebe</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Vocci</surname><given-names>F.J.</given-names></name><collab>PRO-814 Study Group</collab></person-group><article-title>Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial</article-title><source>JAMA</source><volume>316</volume><issue>3</issue><year>2016</year><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.9382</pub-id><pub-id pub-id-type="pmid">27434441</pub-id></element-citation></ref><ref id="bib0102"><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name name-style="western"><surname>Sams&#243; Jofra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Puig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sol&#224;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Trujols</surname><given-names>J.</given-names></name></person-group><article-title>Interim opioid agonist treatment for opioid addiction: a systematic review</article-title><source>Harm Reduct. J.</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12954-022-00592-x</pub-id><pub-id pub-id-type="pmid">35090475</pub-id><pub-id pub-id-type="pmcid">PMC8800211</pub-id></element-citation></ref><ref id="bib0103"><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name name-style="western"><surname>Schuh</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Johanson</surname><given-names>C.E.</given-names></name></person-group><article-title>Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet</article-title><source>Drug Alcohol Depend.</source><volume>56</volume><issue>1</issue><year>1999</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/s0376-8716(99)00012-5</pub-id><pub-id pub-id-type="pmid">10462093</pub-id></element-citation></ref><ref id="bib0104"><element-citation publication-type="journal" id="sbref0104"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rotrosen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Novo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>EV.</given-names></name></person-group><article-title>Prior national drug abuse treatment clinical trials network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"</article-title><source>Addict. Sci. Clin. Pract.</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13722-021-00223-z</pub-id><pub-id pub-id-type="pmid">33676577</pub-id><pub-id pub-id-type="pmcid">PMC7936466</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Slavova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rock</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Quesinberry</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name></person-group><article-title>Signal of increased opioid overdose during COVID-19 from emergency medical services data</article-title><source>Drug Alcohol Depend.</source><volume>214</volume><year>2020</year><object-id pub-id-type="publisher-id">108176</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108176</pub-id><pub-id pub-id-type="pmcid">PMC7351024</pub-id><pub-id pub-id-type="pmid">32717504</pub-id></element-citation></ref><ref id="bib0106"><element-citation publication-type="journal" id="sbref0106"><person-group person-group-type="author"><name name-style="western"><surname>Sordo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Indave</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wiessing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastor-Barriuso</surname><given-names>R.</given-names></name></person-group><article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies</article-title><source>BMJ</source><volume>357</volume><year>2017</year><fpage>j1550</fpage><pub-id pub-id-type="doi">10.1136/bmj.j1550</pub-id><pub-id pub-id-type="pmid">28446428</pub-id><pub-id pub-id-type="pmcid">PMC5421454</pub-id></element-citation></ref><ref id="bib0107"><element-citation publication-type="journal" id="sbref0107"><person-group person-group-type="author"><name name-style="western"><surname>Soyka</surname><given-names>M</given-names></name></person-group><article-title>Treatment of opioid dependence with buprenorphine: current update</article-title><source>Dialogues Clin. Neurosci.</source><volume>19</volume><issue>3</issue><year>2017</year><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2017.19.3/msoyka</pub-id><pub-id pub-id-type="pmid">29302227</pub-id><pub-id pub-id-type="pmcid">PMC5741113</pub-id></element-citation></ref><ref id="bib0108"><element-citation publication-type="journal" id="sbref0108"><person-group person-group-type="author"><name name-style="western"><surname>Spreen</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Dittmar</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Quirk</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name></person-group><article-title>Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review</article-title><source>Pharmacotherapy</source><volume>42</volume><issue>5</issue><year>2022</year><fpage>411</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1002/phar.2676</pub-id><pub-id pub-id-type="pmid">35302671</pub-id><pub-id pub-id-type="pmcid">PMC9310825</pub-id></element-citation></ref><ref id="bib0109"><element-citation publication-type="journal" id="sbref0109"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Sorbero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Pacula</surname><given-names>R.L.</given-names></name></person-group><article-title>A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees</article-title><source>Subst. Abus.</source><volume>39</volume><issue>4</issue><year>2018</year><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1080/08897077.2018.1449166</pub-id><pub-id pub-id-type="pmid">29932847</pub-id><pub-id pub-id-type="pmcid">PMC6309581</pub-id></element-citation></ref><ref id="bib0110"><mixed-citation publication-type="other" id="sbref0110">Substance Abuse and Mental Health Services Administration (SAMHSA), 2021a. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey On Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, Maryland. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf" id="interref0012">https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0111"><mixed-citation publication-type="other" id="sbref0111">Substance Abuse and Mental Health Services Administration (SAMHSA), 2021b. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020, Data on Substance Abuse Treatment Facilities. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, Maryland. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/sites/default/files/reports/rpt35313/2020_NSSATS_FINAL.pdf" id="interref0013">https://www.samhsa.gov/data/sites/default/files/reports/rpt35313/2020_NSSATS_FINAL.pdf</ext-link> (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0112"><mixed-citation publication-type="other" id="sbref0112">Substance Use-disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, Pub. L. No 115-271, 2018. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.govinfo.gov/content/pkg/PLAW-115publ271/html/PLAW-115publ271.htm" id="interref0014">https://www.govinfo.gov/content/pkg/PLAW-115publ271/html/PLAW-115publ271.htm</ext-link> (Accessed December 14, 2022)</mixed-citation></ref><ref id="bib0113"><element-citation publication-type="journal" id="sbref0113"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bagley</surname><given-names>S.M.</given-names></name></person-group><article-title>Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment</article-title><source>J. Gen. Intern. Med.</source><volume>36</volume><issue>12</issue><year>2021</year><fpage>3810</fpage><lpage>3819</lpage><pub-id pub-id-type="doi">10.1007/s11606-021-06904-4</pub-id><pub-id pub-id-type="pmid">34159545</pub-id><pub-id pub-id-type="pmcid">PMC8218967</pub-id></element-citation></ref><ref id="bib0114"><mixed-citation publication-type="other" id="sbref0114">Titan Pharmaceuticals, Inc., 2022, June. PROBUPHINE&#174; Full Prescribing Information. San Francisco, CA. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204442s012lbl.pdf" id="interref0015">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204442s012lbl.pdf</ext-link> (Accessed December 15, 2022).</mixed-citation></ref><ref id="bib0115"><mixed-citation publication-type="other" id="sbref0115">US Department of Health and Human Services (HHS), Office of the Surgeon General, 2018. Facing Addiction in America: The Surgeon General's Spotlight On Opioids. HHS, Washington, D.C. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://addiction.surgeongeneral.gov/sites/default/files/Spotlight-on-Opioids_09192018.pdf" id="interref0016">https://addiction.surgeongeneral.gov/sites/default/files/Spotlight-on-Opioids_09192018.pdf</ext-link> (Accessed December 14, 2022)</mixed-citation></ref><ref id="bib0116"><mixed-citation publication-type="other" id="sbref0116">US Food and Drug Administration (FDA), n.d.a. DRUGS@FDA: fDA-approved drugs. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=204242" id="interref0017">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=204242</ext-link> (Accessed October 7, 2022).</mixed-citation></ref><ref id="bib0117"><mixed-citation publication-type="other" id="sbref0117">US FDA,&#160; n.d.b. DRUGS@FDA: fDA-approved drugs. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=205637" id="interref0018">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=205637</ext-link> (Accessed October 7, 2022).</mixed-citation></ref><ref id="bib0118"><mixed-citation publication-type="other" id="sbref0118">US FDA,&#160; n.d.c. DRUGS@FDA: FDA-approved drugs. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=208042" id="interref0019">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=208042</ext-link> (Accessed October 7, 2022).</mixed-citation></ref><ref id="bib0119"><mixed-citation publication-type="other" id="sbref0119">US FDA, 1972. Methadone Listing as New Drug With Special Requirements and Opportunity for Hearing in: Federal Register Volume 37, Issue 242 (December 15, 1972). Office of the Federal Register, National Archives and Records Administration, Washington, D. C., pp. 26790&#8211;26807. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.govinfo.gov/content/pkg/FR-1972-12-15/pdf/FR-1972-12-15.pdf" id="interref0020">https://www.govinfo.gov/content/pkg/FR-1972-12-15/pdf/FR-1972-12-15.pdf</ext-link> (Accessed December 14, 2022)</mixed-citation></ref><ref id="bib0120"><mixed-citation publication-type="other" id="sbref0120">US FDA, 2009, December. Guidance for Industry Patient-Reported Outcome Measures: use in Medical Product Development to Support Labeling Claims. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/77832/download" id="interref0021">https://www.fda.gov/media/77832/download</ext-link> (Accessed October 7, 2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1477-7525-4-79</pub-id><pub-id pub-id-type="pmcid">PMC1629006</pub-id><pub-id pub-id-type="pmid">17034633</pub-id></mixed-citation></ref><ref id="bib0121"><mixed-citation publication-type="other" id="sbref0121">US FDA, 2020, October. Opioid Use Disorder: endpoints for Demonstrating Effectiveness of Drugs Guidance for Industry, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/114948/download" id="interref0022">https://www.fda.gov/media/114948/download</ext-link> (Accessed October 7, 2022).</mixed-citation></ref><ref id="bib0122"><mixed-citation publication-type="other" id="sbref0122">US FDA, 2022. Orange Book: approved Drug Products with Therapeutic Equivalence Evaluations. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm" id="interref0023">https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm</ext-link>. (Accessed December 14, 2022).</mixed-citation></ref><ref id="bib0123"><element-citation publication-type="journal" id="sbref0123"><person-group person-group-type="author"><name name-style="western"><surname>Vocci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name></person-group><article-title>Medications development: successes and challenges</article-title><source>Pharmacol. Ther.</source><volume>108</volume><issue>1</issue><year>2005</year><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2005.06.010</pub-id><pub-id pub-id-type="pmid">16083966</pub-id></element-citation></ref><ref id="bib0124"><element-citation publication-type="journal" id="sbref0124"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Lofwall</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Vince</surname><given-names>B.</given-names></name><name name-style="western"><surname>Levy-Cooperman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kelsh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coe</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Nuzzo</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Tiberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial</article-title><source>JAMA Psychiatry</source><volume>74</volume><issue>9</issue><year>2017</year><fpage>894</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.1874</pub-id><pub-id pub-id-type="pmid">28655025</pub-id><pub-id pub-id-type="pmcid">PMC5710238</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Stitzer</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>G.E.</given-names></name></person-group><article-title>Clinical pharmacology of buprenorphine: ceiling effects at high doses</article-title><source>Clin. Pharmacol. Ther.</source><volume>55</volume><issue>5</issue><year>1994</year><fpage>569</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/clpt.1994.71</pub-id><pub-id pub-id-type="pmid">8181201</pub-id></element-citation></ref><ref id="bib0126"><element-citation publication-type="journal" id="sbref0126"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name></person-group><article-title>COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States</article-title><source>Mol. Psychiatry</source><volume>26</volume><issue>1</issue><year>2021</year><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-00880-7</pub-id><pub-id pub-id-type="pmid">32929211</pub-id><pub-id pub-id-type="pmcid">PMC7488216</pub-id></element-citation></ref><ref id="bib0127"><element-citation publication-type="journal" id="sbref0127"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Makowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farquharson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beebe</surname><given-names>K.L.</given-names></name></person-group><article-title>Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence</article-title><source>Drug Alcohol Depend.</source><volume>103</volume><issue>1&#8211;2</issue><year>2009</year><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.03.008</pub-id><pub-id pub-id-type="pmid">19403243</pub-id></element-citation></ref><ref id="bib0128"><element-citation publication-type="journal" id="sbref0128"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>J.S.H.</given-names></name><name name-style="western"><surname>Nikoo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Westenberg</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Suen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.Y.C.</given-names></name><name name-style="western"><surname>Krausz</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sch&#252;tz</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sidhu</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Moe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arishenkoff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Griesdale</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>N.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>P.</given-names></name></person-group><article-title>Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial</article-title><source>Addict. Sci. Clin. Pract.</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s13722-021-00220-2</pub-id><pub-id pub-id-type="pmid">33579359</pub-id><pub-id pub-id-type="pmcid">PMC7881636</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgments</title><p id="para0052">CH contributed to the concept and design of this review, drafting of the manuscript and revising it critically for important intellectual content. PJF and MKG contributed to the drafting of the manuscript and revising it critically for important intellectual content. All authors approved the final version of the submitted manuscript.</p></ack></back></article></pmc-articleset>